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ABSTRACT 
INTRODUCTION: Breast cancer is a highly heterogeneous disease. The 
complexity of achieving an accurate diagnosis and an effective treatment regimen 
lies within this heterogeneity. Subtypes of the disease are not simply molecular, 
i.e. hormone receptor over-expression or absence, but the tumour itself is 
heterogeneous in terms of tissue of origin, metastases, and histopathological 
variability. Accurate tumour classification vastly improves treatment decisions, 
patient outcomes and 5-year survival rates. Gene expression studies aided by 
transcriptomic technologies such as microarrays and next-generation sequencing 
(e.g. RNA-Sequencing) have aided oncology researcher and clinician 
understanding of the complex molecular portraits of malignant breast tumours. 
Mechanisms governing cancers, which include tumorigenesis, gene fusions, gene 
over-expression and suppression, cellular process and pathway involvement, have 
been elucidated through comprehensive analyses of the cancer transcriptome. 
Over the past 20 years, gene expression signatures, discovered with both 
microarray and RNA-Seq have reached clinical and commercial application 
through the development of tests such as Mammaprint®, OncotypeDX®, and 
FoundationOne® CDx, all which focus on chemotherapy sensitivity, prediction of 
cancer recurrence, and tumour mutational level.  
The Gene Expression Barcode (GExB) algorithm was developed to allow for easy 
interpretation and integration of microarray data through data normalization with 
frozen RMA (fRMA) preprocessing and conversion of relative gene expression to 
a sequence of 1's and 0's. Unfortunately, the algorithm has not yet been developed 
for RNA-Seq data. However, implementation of the GExB with feature-selection 
would contribute to a machine-learning based robust breast cancer and subtype 
classifier. 
METHODOLOGY: For microarray data, we applied the GExB algorithm to 
generate barcodes for normal breast and breast tumour samples. A two-class 
classifier for malignancy was developed through feature-selection on barcoded 
samples by selecting for genes with 85% stable absence or presence within a 
tissue type, and differentially stable between tissues. A multi-class feature-
selection method was employed to identify genes with variable expression in one 
subtype, but 80% stable absence or presence in all other subtypes, i.e. 80% in n-1 
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subtypes.  
For RNA-Seq data, a barcoding method needed to be developed which could 
mimic the GExB algorithm for microarray data. A z-score-to-barcode method was 
implemented and differential gene expression analysis with selection of the top 
100 genes as informative features for classification purposes. 
The accuracy and discriminatory capability of both microarray-based gene 
signatures and the RNA-Seq-based gene signatures was assessed through 
unsupervised and supervised machine-learning algorithms, i.e., K-means and 
Hierarchical clustering, as well as binary and multi-class Support Vector Machine 
(SVM) implementations.  
RESULTS: The GExB-FS method for microarray data yielded an 85-probe and 
346-probe informative set for two-class and multi-class classifiers, respectively. 
The two-class classifier predicted samples as either normal or malignant with 
100% accuracy and the multi-class classifier predicted molecular subtype with 
96.5% accuracy with SVM. 
Combining RNA-Seq DE analysis for feature-selection with the z-score-to-
barcode method, resulted in a two-class classifier for malignancy, and a multi-
class classifier for normal-from-healthy, normal-adjacent-tumour (from cancer 
patients), and breast tumour samples with 100% accuracy. Most notably, a 
normal-adjacent-tumour gene expression signature emerged, which differentiated 
it from normal breast tissues in healthy individuals. 
CONCLUSION: A potentially novel method for microarray and RNA-Seq data 
transformation, feature selection and classifier development was established. The 
universal application of the microarray signatures and validity of the z-score-to-
barcode method was proven with 95% accurate classification of RNA-Seq 
barcoded samples with a microarray discovered gene expression signature. The  
results from this comprehensive study into the discovery of robust gene 
expression signatures holds immense potential for further R&F towards 
implementation at the clinical endpoint, and translation to simpler and cost-
effective laboratory methods such as qtPCR-based tests.  
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Chapter 1 
Literature Review 
 
The pairing of biological data and computational algorithms has contributed to 
new classification models of cancer. Past and current high throughput analysis of 
cells and tissues is revolutionizing biomedical and biological research. 
Completion of the whole human genome, discoveries of gene sequence and 
annotation along with the development of microarray technology, and more 
recently, next-generation sequencing (NGS) technologies, over the past 15 years 
has seen characterization of cells and tissues in greater depth. Although our 
knowledge of the human genome has improved vastly, genomic data does not 
provide enough information on the differentiation of cell types, while 
Transcriptomic data has proven to be more informative. Despite these 
advancements, there have been little to no big advances in diagnosis or treatment 
(McCall, Uppal, Jaffee, Zilliox, & Irizarry, 2011; Zilliox & Irizarry, 2007a). 
 
The vast amount of publicly available gene expression data has seen a move 
towards classification models for cancer from gene expression profiling. The 
profiling entails examination of the differential expression of genes and their 
unique combinations in different states of the cancerous tissues and healthy tissue. 
Gene signatures have been developed which can predict cancer subtype and 
prognosis, such as Mammaprint® and Oncotype® DX. The robust nature of 
machine learning algorithms has accelerated and assisted the design of such 
signatures through application of the mathematical and data sciences to 
biomedical questions. 
 
1.1 Machine Learning 
Machine learning encompasses the design and application of algorithms that 
enable the use of existing data to establish models for pattern recognition, 
classification and prediction (Alpaydin, 2010). The aim of automatic model 
construction approaches is to minimize human biases and errors that could skew 
selection and performance of the algorithm, while enabling the discovery of subtle 
http://etd.uwc.ac.za/
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patterns and associations between data points. Over the years, machine learning 
techniques have become more pliable and have been expanding together with 
mathematical frameworks for measuring reliability. The coupling has led to 
improving the efficiency and accuracy of discoveries made in biology and 
understanding complex biological data (Sommer & Gerlich, 2013; Tarca, Carey, 
Chen, Romero, & Drǎghici, 2007).  
 
Within machine learning, two exemplars exist; supervised and unsupervised 
learning. Supervised learning entails a sample or group using a feature set of 
attributes such as genes. The resultant classification scheme is a set of rules that 
designate objects based on the values of the features. The primary objective of 
supervised learning is to construct a system capable of accurately predicting the 
class “membership” of an object. Other than accurate classification of unknown 
objects, supervised machine learning also aims to be able to predict possible 
outliers in data; those instances that do not specifically match any of the 
predefined classes according to the features selected by the algorithms designed. 
An example of object-to-class assignments, in a biological setting, would be 
classification of tissue gene expression profiles to disease group (Libbrecht, 
Noble, & Genome, 2017).  
 
Unsupervised learning, conversely, has no predefined class labels for the data to 
be studied. The aim instead is to simultaneously analyse the data and observe 
similarities between objects. The similarities observed, called clusters would 
define groups of objects. Hence, unsupervised learning's intention is to reveal 
naturally occurring groupings of objects based on the measurements of specific 
features in data (Yip, Cheng, & Gerstein, 2013) 
 
1.1.1 Different Machine Learning classifiers and algorithms 
1.1.1.1 K-means clustering 
Clustering algorithms are considered to be a form of unsupervised learning. Data 
instances that share similarities are grouped together. The algorithm can only 
access data about the features describing each object. However, in real 
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applications of clustering, the scientist usually has some knowledge about the 
dataset (Wagstaf, Cardie, Rogers, & Schroedl, 2001). Data clustering can be 
separated into two types, namely hierarchical and partitional clustering.  
 
K-means clustering is classified as a partitional clustering algorithm. The method 
finds a partition that separates data (Jain & Dubes, 1988) by minimizing the 
squared error between the emperical mean of a cluster and the data instances, 
called points, of the said cluster. The main aim of the K-means algorithm is to 
minimize the squared error of all the clusters specified for a given dataset being 
investigated for classification (Drineas, Frieze, Kannan, Vempala, & Vinay, 
2004). 
 
The algorithm first selects k initial clusters, then for a specific data instance, x, 
assigns it to the closest related cluster centers. Every time a new data instance is 
added to the dataset, the cluster center is re-computed to be the average (mean) of 
its constituent data instances. K-means converges when there are no changes 
made to the clusters formed; the squared error of the cluster's mean is minimized 
and the cluster is centred (MacQueen, 1967).  
 
Distance metrics are used to compute the distance between related samples or data 
instances in a cluster and also the distance between the different clusters. 
Euclidean distance, a metric based on the Pythagoras theorem of points in a 
dimensional plane, is applied in K-means clustering (Mao & Jain, 1996).  
 
1.1.1.2 Hierarchical Clustering 
Hierarchical clustering is based on variants of primarily three algorithms; single-
link (King, 1967), complete-link (Sneath & Sokal, 1962), and multi-variance 
(Murtagh, 1984; Ward, 1963). The two most broadly used algorithms in 
hierarchical clustering are single-link and complete-link, however, the two 
algorithms are distinctive in the manner in which they separate and characterize 
clusters of similarity. The hierarchy of clusters formed from the single-link 
algorithm can easily be used to construct dendograms; allowing the easy 
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visualization of clusters formed. The visualization of hierarchical clustering is 
depicted in a tree-like format, a dendogram, and branches correlate to the data 
instances being clustered (D’haeseleer, 2005), with closely related data clustering 
together as one big branch. Dendograms are particularly useful for classification 
applications within biological settings. 
 
Nested clusters, data instances or samples branching from the main branches of 
the dendogram, are found either in an agglomerative or a divisive manner. The 
agglomerative mode entails starting with each data point in its own cluster and 
merging the most similar clusters in successive order to form a hierarchy. The 
divisive mode separates and organizes all data points from a single large cluster 
into smaller clusters (Jain, 2010).  
 
Figure 1. 1: An example of K-means clustering where k = 3 (Jain, 
2009.
http://etd.uwc.ac.za/
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Figure 1. 2: An example of a dendogram generated from hierarchical clustering. (Jain, 
2009). 
 
1.1.1.3 Neural Networks 
Artificial Neural Networks (ANNs) are essentially mathematical models that were 
developed based on how biological nervous systems function and transmit signals 
and impulses. ANNs are a form of supervised learning, which is commonly 
categorised as semi-supervised learning. It uses a feed forward network; signals 
which can be represented by variables such as genes which are either mutated or 
gene expression levels of a specific cell, are inseminated through the layers of 
units. The units referred to mimic neurons, and are referred to as nodes (Abraham, 
2005). 
 
Usually three units make up the network; (1) an input layer, which is in most 
cases fed with gene expression data, (2) a hidden layer(s) of units, and (3) an 
output layer, one for each classification of tissue, in a biological instance 
(Mitchell, 1997). The connections formed between the layers are assigned 
weights, which are adjusted during the training phase of machine learning. With 
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back-propagation neural networks, the algorithm adjusts the weights by back-
propagating the error between the units until the best fit for the training data is 
found (Statnikov, Aliferis, Tsamardinos, Hardin, & Levy, 2005). The weights are 
modelled on neuronal synapses and input signals are disseminated in a non-linear 
fashion as to simulate how signals are transmitted by neurons (Abraham, 2005). 
 
Commonly used NN algorithms include Forward Propagation, Back Propagation, 
and Probabilistic Neural Networks (Mitchell, 1997). 
 
1.1.1.4 Self-Organizing Maps (SOMs) 
SOMs can be viewed as a derivative of Artificial Neural Networks. Data 
dimension reduction is the main objective of SOMs and is primarily a qualitative 
data visualization tool. The algorithm learns the classification, topology and 
distribution of input vectors. Neurons or nodes are assigned according to the 
amount of input vectors. Nodes in close proximity to each other learn to respond 
to similar input data.  
 
The algorithm is designed such that data regularities and correlations are detected; 
resulting in future response being adapted accordingly. Data visualization aims to 
solve humans' inability to visualize high-dimensional data through mapping data 
in a 1- or 2-dimensional space. SOMs generate maps that plot data instance 
similarities into clusters (Abraham, 2005). The machine learning application itself 
is unsupervised. 
 
1.1.1.5 Support Vector Machines (SVMs) 
Support Vector Machines (SVM) was initially developed for two-class 
classification problems. The aim was to develop an algorithm capable of robust 
pattern recognition that would have high generalization ability with minimal 
errors in the training datasets. Polynomial and radial basis function equations were 
used to obtain optimal margins that would separate two classes within a training 
set (Cortes & Vapnik, 1995).  SVM has been shown to classify data with superior 
accuracy to other supervised machine learning algorithms like early ANN's and 
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ensemble classification methods (Statnikov et al., 2005). The applications of 
SVM's vary from text-categorization technologies (Joachims, 1998), to facial 
recognition software (Osuna, Freund, & Girosit, 2000), to biological 
implementation in disease classification like cancer and bacterial infections (Su et 
al., 2001).  
 
1.1.1.5.1 Binary SVMs 
Support Vector Machines are considered one of the most reliable forms of 
machine learning (Furey et al., 2000). Initially designed for binary, or two-class 
classification, the algorithm maps data instances to a dimensional space. A 
maximum-margin margin hyperplane is then identified to separate training 
instances (Vapnik, 1998). The set of training instances used to construct the 
boundary or hyperplane, are referred to as support vectors. When an unknown 
data sample is introduced, the algorithm will classify it based on the side of the 
hyperplane it falls into (Statnikov et al., 2005). 
 
 
Figure 1. 3: An example of a binary, two-class SVM with hyperplane construction 
(Statnikov et al., 2005). 
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1.1.1.5.2 Multi-class SVMs 
Multi-class SVMs arose as the need for multi-category classification for disease 
and industry arose. The most commonly used amendments of the binary SVM 
algorithms are the One-versus-Rest (OVR) and the One-versus-One (OVO) 
adaptations (Ulrich, 1999). The OVR method constructs k binary SVM classifiers: 
class 1 (positive) versus all the other classes and proceeds to do the same for all k 
classes in the experiment. The combined decision function would correlate to the 
maximum value of k binary decision functions. The OVO method, builds binary 
classifiers for all pairs of classes. Subsequently, a binary problem is solved: a 
decision function assigns an instance to a class with the largest number of votes. 
Recent studies have revealed that the OVR multi-class SVM algorithm has 
superior classification performance which is further enhanced when feature-
selection methods are applied to data preceding SVM classification (Statnikov et 
al., 2005). 
 
1.2 Application of Machine Learning (ML) in Biomedical Scenarios 
Machine learning has the ability to solve classification problems in real world 
medical diagnosis. The development of algorithms such as Artificial Neural 
Networks (NN), Decision Trees, k-Nearest Neighbour (kNN), and Support Vector 
Machines (SVM) have assisted in both disease diagnosis and classification but 
also the interpretation of biological data from technologies like PCR, Microarray 
assays, and DNA- and RNA-sequencing data (Kourou, Exarchos, Exarchos, 
Karamouzis, & Fotiadis, 2015). 
 
Bioinformatics has been able to make progress in fields relating to disease 
diagnosis and mechanism through genomic and proteomic function prediction. 
Applications of machine learning to systems biology include: protein-coding 
genes, protein function prediction, protein-RNA interactions (Caragea & Honavar, 
2009), and the impact of these genetic factors on cell regulation and function.  
 
Machine learning has been applied extensively in cancer classification from gene 
expression profiles (Kourou et al., 2015). 
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Artificial intelligence has been used in cancer prediction and prognosis for more 
than 25 years; predominantly with applications of NN's and decision trees 
(Cichetti, 1992). The diagnosis of cancers is not only achieved through gene 
expression analysis, but also from tumour biopsy histopathological examinations, 
X-rays and CRT images. Machine learning algorithms have contributed to 
accurate classification of tumours using data from all of these technologies (Liotta 
& Petricoin, 2000; Zhou, Liu, & Wong, 2004). The accurate prediction of cancer 
susceptibility and diagnosis, which integrates both macro (physical) and 
microscopic (genetic) data, has vastly improved through the application of 
machine learning algorithms. Furthermore, ML has assisted in the identification of 
novel disease biomarkers and drug targets (Cruz & Wishart, 2006). 
 
1.3 Feature Selection 
Irrelevant information is part of raw data generated from biological studies 
(Guyon, Weston, Stephen, & Vapnik, 2002). The need for Feature Selection (FS) 
techniques in bioinformatics has therefore grown in recent years, as it is now a 
requirement in the building of models for real-world applications. Originally, the 
designs for pattern recognition software were not built to manage large amounts 
of data. Due to the high dimensionality of biological data used in computational 
biology, dimension reduction is implemented to facilitate the interpretation of 
data. Feature selection offers dimension reduction without the loss of the original 
data representation, and merely selects a subset of the definitive properties of a 
data instance, e.g. genes expressed. FS can be applied to both supervised and 
unsupervised machine learning algorithms and classifiers (Liu & Yu, 2005). 
 
The three main aims of FS approaches include: (1) to avoid over-fitting and 
improve model performance, (2) to provide faster and more cost-effective models, 
and (3) to gain deeper insight into the underlying processes that generated the 
data. Selection of features cannot be dependent of the parameters of the optimized 
machine learning algorithm applied or classification model under investigation. 
Idealistically, the optimal model parameters and optimal feature set are paired  
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(Daelemans & Hoste, 2002). Within classification schemes, there are three 
categories of FS methods; filter, wrapper and embedded methods. Each differ in 
how they are implemented with the construction of the classification model 
(Saeys, Inza, & Larrañaga, 2007).  
 
1.3.1 Feature Selection techniques 
Filter techniques evaluate the relevance of features by taking only intrinsic 
properties of the data into account. The approach calculates a feature relevance 
score, and low-scoring features are removed from the original feature set (Saeys et 
al., 2007). Features selected must be relevant for prediction, but redundant 
features should be minimized. Relevance criteria measures how well a feature, 
e.g. a gene expressed or microarray chip probe, distinguishes between classes of 
data. Criteria like  Symmetric Uncertainty (SU), Spearman rank correlation 
coefficient (CC), Value Difference Metric (VDM), Fit Criterion (FC) measure 
how useful a variable is for predicting the class of a data instance (Auffarth, 
2010). Thereafter, the set of features selected are presented as input to the 
classification algorithm.  
 
Wrapper techniques embed the model hypothesis search within the feature subset 
search. With wrapper methods, a search protocol in the space of possible feature 
subsets is defined, and various subsets of features are generated and evaluated. 
The evaluation of a specific subset of features is obtained by training and testing a 
specific classification model, rendering this approach tailored to a specific 
classification algorithm. To search the space of all feature subsets, a search 
algorithm is then ‘wrapped’ around the classification model.  
 
With embedded techniques, the search for an optimal subset of features is built 
into the classifier construction itself, and can be seen as a search in the combined 
space of feature subsets and hypotheses. This method interacts with the classifier 
and is better computationally when compared to wrapper methods. The embedded 
approach is also capable of modelling feature dependencies. As with wrapper 
approaches, embedded approaches are thus specific to a given learning algorithm 
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(Saeys et al., 2007). 
 
1.3.2 Dimension reduction of expression microarray data using feature 
selection 
Univariate filter techniques are most favoured in dimension reduction of 
microarray data. The method is fast and efficient, yet simple. In comparative 
studies of different classification algorithms paired with feature selection, the 
filter method is most prevalent in evaluation and investigation of DNA and 
mRNA microarray datasets  (Dudoit, Fridlyand, & Speed, 2002; J. W. Lee, Lee, 
Park, & Song, 2005; Li, Zhang, & Ogihara, 2004). Reasons for this include; the 
output of feature ranking is easy to understand, the gene-ranking output fulfils the 
objectives of bio-domain experts that want to validate results in laboratories, and 
short computation time for data analysis (Saeys et al., 2007). 
 
However, univariate approaches have restrictions, and in some instances lead to 
less accurate classifiers as they ignore gene-gene interactions. FS techniques using 
wrapper or embedded methods, can offer a way to perform multivariate gene 
subset selection  (Saeys et al., 2007). Hybrid methods that incorporate univariate 
pre-selection with multivariate altered wrapper methods have also been proposed 
in the case of cancer classification (Ruiz, Riquelme, & Aguilar-Ruiz, 2006). 
 
1.4 Microarrays and Gene-expression signatures 
1.4.1 Microarray Technology 
Microarray chips are designed to generate gene expression measures from cell and 
tissue samples by using cellular mRNA to elucidate gene up-regulation and down-
regulation in different tissues; ranging from biological to agricultural settings. 
Nucleic acid microarrays make use of short oligonucleotides (15-25 nt), long 
oligonucleotides (50-120 nt), and PCR-generated complimentary DNA (cDNAs) 
(100-3000 base pairs) as array elements (Miller & Tang, 2009; Stears, Martinsky, 
& Schena, 2003).  
 
Short oligonucleotides and cDNAs have both been shown to perform well for 
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expression analysis. However, each has its own drawback. Short oligonucleotides 
can lack single-gene specificity in complex hybridizations. On the other hand, 
PCR-generated cDNAs produce strong signals and high specificity (Schena, 1996; 
Lockhart et.al., 1996; Yuen et.al., 2002). Long oligonucleotides produce strong 
hybridization signals, good specificity and the ability to unambiguously identify 
transcripts within samples; but are dependent on the availability of genomic 
sequence information for each species under study (Kane et.al., 2000).  
 
Expansion of traditional microarrays into exon arrays has allowed for larger 
coverage of exon regions of genes, and has been termed as whole transcript 
arrays. This is also largely due to an increase in array features, by decreasing the 
number of probes (Okoniewski & Miller, 2008). Gene alternative splicing through 
hybridization of variant transcript isoforms is detectable by exon arrays, along 
with expression levels of each exon independently (Bemmo et al., 2008; Kapur, 
Xing, Ouyang, & Wong, 2007).  
 
1.4.2 Expression Profiling 
Quantitative gene expression data is generated by transcript profiling. In order for 
profiling to take place, one- or two-colour fluorescent schemes are implemented 
(R. J. Cho et al., 1998), and the most broadly used and easily interpreted scheme 
is two-colour fluorescence. Each RNA sample is labelled with two different 
fluorescent tags prior to hybridization with cDNA. Visualization of genes that are 
“activated” or “repressed” is produced from two-colour graphical 
superimposition. The two-colour graphic representation of probes expressing 
genes at different levels, allows the separation and comparison of various tissues 
based on their respective expression profiles. This process allows for the 
throughput of high quality gene expression data (S. M. Y. Lee et al., 2002). 
 
Detection of fluorescent probes (tags attached to oligonucleotides/genes) is 
achieved with instruments that contain confocal optics, photomultiplier tubes, and 
charge-coupled devices. The detection instruments render graphical images in 
tagged-image file format (TIFF), which are two-dimensional, 16-bit numerical 
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representations of microarray surfaces with intensity values assigned. These 
numerical values are then interpreted as expression values of genes (Carr, 
Somogyi, & Michaels, 1997). The data collected is raw data, and sequentially 
further data analysis which includes transformation and normalization of data is 
necessary for extrapolation of biologically significant knowledge from machine 
learning algorithm applications and microarray analysis software (Stears et al., 
2003). 
 
1.4.3 Microarray data analysis 
In order for microarray data to become useful in biological settings, a wide range 
of data analysis and processing is required. The two most important components 
of the analysis are design and pre-processing. Both are necessary steps preceding 
the classification of genes, cells and tissues, as well as validation of data (Allison, 
Cui, Page, & Sabripour, 2006).  
 
Design: How the microarray experiments and the relevant study is designed 
impacts efficiency and validity of experiments. Within the design of a study, there 
are certain optimization steps that can be employed (Kerr, 2003). Firstly, 
biological replication is imperative. There are two forms of replication which can 
be applied to microarray experiments, which include technical and/or biological 
replication (Churchill, 2002; Yang, Buckley, & Speed, 2001). Secondly, the 
pooling of biological samples may further assist design optimization. This is due 
to the fact that when trying to ascertain and identify differential gene expression, 
high data variability can be eliminated from a study (Kendziorski, Irizarry, Chen, 
Haag, & Gould, 2005). And thirdly, avoiding confounding by extraneous factors 
is vital. When such factors vary with the independent variable of the experiment, 
it may yield confusing and erroneous conclusions of a study (Kerr, 2003). 
 
Preprocessing: Image analysis and data normalization and transformation form 
part of pre-processing. These steps are required in order to remove systematic 
variation in the data. Normalization of data from different experiments and chip 
platforms is necessary to account not only for background noise (mismatched 
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probes), but also technical variance of fluorescence readings, which infer up- and 
down-regulation of gene expression, of microarray chips. Data transformation 
typically describes mathematical formulas being applied to data to change the 
format. Most often, log2 is applied to numerical values produced from micro-array 
detection technologies (Allison et al., 2006). 
 
The most broadly applied micro-array data normalisation algorithm used is called 
robust multi-array average (RMA), designed for use on Affymetrix and 
Nimblegen microarray platforms (Irizarry, Bolstad, et al., 2003). The algorithm 
corrects data for background noise by transforming the data. Normalization by the 
algorithm is performed with a formula that uses normal distribution and a linear 
model to estimate expression values on a log scale). An alteration to RMA is 
GCRMA, which corrects for the GC content of the oligonucleotides used in the 
initial microarray chip experiment (Bolstad, Irizarry, Åstrand, & Speed, 2003).  
 
1.4.4 Frozen Robust Microarray Analysis (fRMA) 
The use of gene expression microarray experiments has become broadly used for 
research in biological studies. Methods for data analysis have had to adapt to the 
various aspects that affect micro-array data, such as batch effects, noise and 
reproducibility of experiments. Micro-array analysis consists firstly, of 
preprocessing the probe-level fluorescent readings to gene-level expression 
estimates. This initial step requires algorithms to resolve multiple or batches of 
arrays together (Bolstad et al., 2003). Despite the robust nature of the RMA 
algorithm, the multi-array processing complicates and limits inquiry  (Ramasamy, 
Mondry, Holmes, & Altman, 2008). To process individual array experiments is 
computationally expensive, and introducing data from single arrays cannot be 
combined without introducing noise. This is a real dilemma for applying 
microarray technologies to clinical settings; the requirement is to extract 
actionable information from a single sample as opposed to a batch set of samples 
from an isolated experiment. 
 
The frozen Robust Micro-array Analysis (fRMA) algorithm was hence designed, 
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as it presented a method to pre-process individual array experiments, while 
retaining the advantages of batch array pre-processing (McCall, Bolstad, & 
Irizarry, 2010a). The basis of fRMA is simple; the parameter estimates are pre-
computed on a massive and biologically diverse database of micro-array 
experiments, after which these parameters are frozen. This is then used to pre-
process individual or low sample batches and later condensed for analysis.  
 
1.4.5 The Gene Expression Barcode algorithm 
The complexity of distinguishing tissues based on transcriptomic or microarray 
data is due to the use of relative expression of genes when reporting data, i.e. 
which genes are differentially expressed in one condition compared to others 
(Parkinson et al., 2009). Probe effects and noisy data obfuscate the correlation 
between observed probe intensity and actual expression of a transcript. Knowing 
absolute expression of genes, i.e. whether a gene is expressed or not, instead of 
relative expression of a gene in a tissue type would improve our understanding of 
systems and cellular biology, and provide a starting point for research targeting 
drug discovery and personalized medicine (McCall et al., 2011). 
 
For the above reasons The Gene Expression Barcode project was established. The 
initial barcode algorithm, referred to as Barcode 1.0 (McCall et al., 2011) was 
based on a basic detection method and distance calculation. The rationale behind 
the algorithm was to develop the first method that could clearly demarcate 
expressed from silenced genes; and in so doing, denominate a specific or unique 
gene expression barcode for each tissue type. Vast numbers of raw microarray 
data was curated from publicly available datasets in the Gene Expression 
Omnibus (GEO) and ArrayExpress data repositories and pre-processed with the 
same algorithm. Clinical data from three cancer studies and one Alzheimer’s 
disease study was also collected. The aim was to evaluate which probe intensity 
relates to expression. Thereafter, the intensity distribution for each gene needed to 
be determined. Genes that are shown to be expressed would be classified as ones 
and silenced genes, as zeros. The sequence generated is referred to as the gene 
expression barcode (Zilliox & Irizarry, 2007a).  
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Due to the original barcode methodology only being able to provide absolute 
expression measures for a limited number of genes, the algorithm was extended to 
estimate transcriptomes (McCall et al., 2011). This is motivated by the fact that 
transcriptome data allows insight into what discriminates cell and tissue types, 
hence contributing to the classification of unknown biological samples. In order to 
clearly classify genes as silenced or expressed, one needs clear separation between 
high and low expression values. This is not the case in the majority of genes. The 
original barcode algorithm was further developed to determine a more extensive 
estimate of cell-type transcriptomes by calculating expression calls for all genes 
represented on the array. This was achieved by firstly, establishing a set of 
negative control experiments; secondly, by mass curation of publicly available 
microarray data from  the Affymetrix Human Genome U133A (HGU133a), U133 
Plus 2.0 (HGU133plus2) and Mouse Genome 430 2.0 (Mouse4302) platforms; 
and thirdly, applying the probability of expression (POE) model in a novel setting 
(Parmigiani, Garrett, Anbazhagan, & Gabrielson, 2002). 
 
A new version of the algorithm resulted which produced standardized values; 
allowing for comparison across all genes. The standardized values may be 
translated into absolute expression calls; silenced or expressed genes by 
designation of a single threshold value. The resultant binary values correlating to 
expression calls is called the “barcode” (McCall et al., 2011). Although the Gene 
Expression Barcode Version 3.0 has been extended to include other sequencing 
platforms, a method for barcoding RNA-Seq expression or raw count data has not 
yet emerged (McCall et al., 2014).   
 
One of the other differences in methodology that separates the Gene Expression 
Barcode from other absent/present call algorithms is the approach to microarray 
raw data pre-processing. The common analysis tool for micro-array data is RMA; 
Robust Micro-array Analysis, but the barcode algorithm implements an altered 
algorithm, called frozen Robust Micro-array Analysis (fRMA) (Mccall, Bolstad, 
& Irizarry, 2009). 
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1.4.6 Gene expression profiling in Breast Cancer 
DNA-microarray technologies have provided researchers with the ideal tools and 
opportunities to perform comprehensive molecular and genetic profiling of breast 
cancer (Trevino, Falciani, & Barrera-Saldaña, 2007). Microarray techniques 
provide insights into cell biology as well as developing clinically useful 
classification models. This has allowed clinicians to predict, amongst others, 
disease recurrence and response to different treatments, which promises to 
improve disease management of cancer patients (Cooper, 2001). 
 
1.4.7 Prognostic gene expression profiling 
Over the past years, several breast cancer research groups have conducted gene-
expression profiling studies with the objective of improving on traditional 
prognostic markers. Researchers from the Netherlands Cancer Institute in 
Amsterdam (NKI) reported a 70-gene prognostic signature (Mammaprint™) 
developed on the Agilent platform (Straver et al., 2010).   
 
The sample size consisted of 78 systemically untreated lymph-node-negative 
breast cancers of patients younger than 55 years of age. A year later, 
Mammaprint™ was validated on a larger set of 295 young patients, this time with 
a mixed sample set. The NKI provided proof that the 70-gene signature was the 
strongest predictor for distant metastasis-free survival, independent of adjuvant 
treatment, tumour size, histological grade and age, both in node-negative and 
node-positive cohorts.  
 
A similar study was done by a group in Rotterdam; generating a 76-gene signature 
that was able to determine the development of distant metastases in untreated 
patients of all age groups with node-negative breast cancer (Y. Zhang et al., 
2009). The main difference between the Amsterdam and Rotterdam studies was 
the microarray platform used and the study design used in the development of the 
classifiers. Both classifiers appeared to be good predictors of the development of 
distant metastases within the first 5 years, but showed a decreased prognostic 
ability with the increasing number of follow-up years. 
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1.5 Next-Generation Sequencing 
Sanger sequencing emerged as a “first-generation” sequencing method, and was 
soon widely adopted (Sanger & Coulson, 1975).  Next-generation sequencing 
(NGS) refers to second and third generation sequencing platforms which are able 
to simultaneously sequence millions to billions of sequence reads for 
transcriptome assemblies and analyses (Figueroa, Tang, & Taur, 2014). The past 
ten years has seen the rapid development of various platforms, with slightly 
differing techniques, for the high-throughput sequencing of genomes and 
transcriptomes (Levy & Myers, 2016).  
 
1.5.1 RNA-Seq Technology 
RNA-sequencing (RNA-Seq) is an NGS technique which directly sequences RNA 
transcripts present within a cell or sample (Kukurba & Montgomery, 2015).  The 
exploratory capabilities of RNA-Seq allows for the quantification and detection of 
not only protein-coding RNAs, but also non-coding RNA, miRNA, siRNA, and 
small RNA classes involved in RNA stability, protein translation, or chromatin 
state modulation (Han, Gao, Muegge, Zhang, & Zhou, 2015; Trapnell, Pachter, & 
Salzberg, 2009). As a whole RNA-Seq has allowed for whole transcriptome 
sequencing and analysis, but may also be applied to differing extents depending 
on the objectives of the research question.  
 
Library preparation and sequencing comprises of multiple steps, which rely on 
biochemical interactions of synthetic nucleotides, and enzymes typically involved 
in in vivo DNA replication and/or RNA transcription and translation. Different 
technologies (different companies) achieve this through different techniques: (a) 
Illumina HiSeq/MiSeq technologies incorporate reversible terminator chemistry -  
sequencing by synthesis is achieved through reversible terminator nucleotides 
labelled with a different fluorescent dye, and subsequent imaging detects the 
positioning of these synthetic nucleotides to infer DNA sequence (Ansorge, 
2009). (b) Life Technologies SOLiD sequencing utilises ligation of dinucleotide 
probes with DNA ligase enzymes – 16 different dinucleotide probes (labelled by 
four different colours) are hybridized to a template sequence (RNA fragment), 
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with ligation cycles resetting the primer end to successfully add the correct 
nucleotide complementary to the template (Ku & Roukos, 2013).  
 
Third-generation sequencing (TGS) emerged 5 years ago in the form of Pacific 
Biosciences (PacBio) Single Molecule Real Time (SMRT) platform, and Oxford 
Nanopore technologies (ONT) following closely (Weirather et al., 2017).  Both 
sequencing platforms use a similar technique of detecting clonally amplified 
DNA, as the Illumina platform (Levy & Myers, 2016). (a) PacBio differs from 
Illumina in that it captures a single DNA molecule, and uses circular DNA 
templates with hairpin adapters ligated so that the polymerase reaction synthesises 
a complementary circular strand (Rhoads & Au, 2015). (b) ONT implements a 
nanopore-based single molecule. Single-stranded DNA (ssDNA) is directly 
sequenced, and uses a similar circular DNA template as PacBio.  Sequencing 
occurs by “threading”  of the DNA template through the nanopore, addition of a 
ligated hairpin adaptor, and a complementary strand built via molecular motor 
proteins (Laver et al., 2015). Both PacBio and ONT produce continuous long 
reads (CLR) attributed to the use of circular DNA templates (Rhoads & Au, 
2015). 
 
1.5.2 RNA-Seq Data Analysis 
RNA-Seq produces thousands-to-millions of reads, i.e. sequence fragments, of 
varying lengths. Numerous Python and R packages have been developed 
specifically for the analysis of sequencing data. Prior to any biological 
investigation of the transcriptomic data generated, data pre-processing is 
performed. Quality assessment is the first step in bioinformatics RNA-Seq 
pipelines followed by mapping of the transcript fragments to a reference genome 
in order to ascertain the identity, location, and functions of the sequences (Han et 
al., 2015).   
 
Following alignment of transcripts, gene expression is quantified by counting the 
number of transcript reads mapped to the respective reference genome location 
(Conesa et al., 2016). The gene counts generated from software like HTSeq-count 
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(Anders, Pyl, & Huber, 2015), or featureCounts (Liao, Smyth, & Shi, 2014) can 
be implemented for gene expression analysis, following normalization of raw 
count data. Furthermore, analysis of the aligned transcriptome can be employed to 
identify alternative splicing of genes, variant detection, pathway analysis through 
gene enrichment and discovery of gene co-expression networks (Han et al., 2015; 
Pereira, Imada, & Guedes, 2017).  
 
1.5.3 Application of RNA-Seq within Cancer Studies 
Due to the ability of RNA-Seq to reveal a cell or tissue's entire transcriptome, 
integrative studies into cancer physiology have become possible. There exists a 
strong correlation between a tumour's transcriptome and phenotypic presentation. 
Deep sequencing permits a full view of the genetic regulatory and expression 
mechanisms governing tumorigenesis and pathophysiology of cancer (L. Wan, 
Pantel, & Kang, 2013). NGS has enabled the identification of gene mutations, 
oncogenic gene fusions (Byron, Van Keuren-Jensen, Engelthaler, Carpten, & 
Craig, 2016), methylation abnormalities, chromosomal rearrangements, and gene 
expression alterations within diseases (Ashwag Albukhari, Fawzi F. Bokhari, 
2015). Interrogation of these genetic and transcriptomic cancer-specific traits may 
aid in the diagnosis and prognosis of different cancers and subtypes.  
 
1.5.4 Prognostic and Diagnostic Gene Expression Profiling 
Gene expression profiling for diagnostic biomarker discovery has been 
successfully applied to a number of different cancers. Utilising RNA-Seq data, 
prognostic signatures for invasive lobular breast cancer (Ciriello et al., 2015) , 
pancreatic adenocarcinoma (Kirby et al., 2016), lung adenocarcinoma (Shukla et 
al., 2017), as well as biomarker signatures for cancers of unknown origin (Wei, 
Shi, Jiang, Kumar-Sinha, & Chinnaiyan, 2014). The Cancer Genome Atlas 
consortium has also employed comprehensive analysis with integrative 
transcriptomic studies, through the application of different RNA-Seq and DNA-
Seq platforms, for the discovery of molecular portraits of breast tumours (Koboldt 
et al., 2012), and lung adenocarcinomas (Collisson et al., 2014).  
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1.6 Breast Cancer: Molecular Subtyping through Gene Expression Analysis 
Breast cancer is most frequently diagnosed in women in Western countries and 
accounts for approximately 30% of all cancers diagnosed and 16% of cancer 
deaths (F. Bray et al., 2018). Breast cancer is a clinically, molecularly and 
pathologically heterogeneous disease. Gene expression profiling has allowed the 
identification of molecular breast cancer subtypes. Clinically, the disease has been 
categorized into three basic therapeutic groups. Estrogen positive (ER) breast 
cancer is the most diverse in presentation (Paik et al., 2004). The HER2 subtype, 
is characterized by the presence of HER2 gene, which implicates that the tumour 
is stimulated by elevated levels of growth hormones (Moasser, 2007). Triple-
negative breast cancer tumours do not express any hormonal receptors and are 
essentially progesterone, estrogen and HER2 negative. Triple-negative cancers are 
viewed as the most difficult to treat with the poorest patient survival outcomes 
(Sorlie et al., 2003). 
 
Various clinical and pathological factors, such as age, menopausal status, tumour 
size, histological grade, lymphovascular invasion, oestrogen receptor have been 
implicated as prognostic indicators of clinical course (Perou et al., 2000). Primary 
treatments consist of tumour excision and radiation or mastectomy with or 
without radiotherapy. Adjuvant therapies have been shown to improve the long-
term survival of patients (Dinh, Sotiriou, & Piccart, 2007). 
 
1.7 Research Rationale 
The burden of breast cancer incidence and prevalence in both developed and 
developing countries has motivated the continual research on treatment 
biomarkers and more accurate classification models. Heterogeneous diseases like 
breast cancer require investigation into the genetic differences between diseased 
and healthy states through gene expression profiling. Large public repositories 
exist, such as NCBI, GEO and Array express, containing thousands of mRNA and 
cDNA microarray data samples. This provides researchers with an abundance of 
reusable data from which novel biological insights and predictive diagnostics can 
be developed in a cost-effective manner. The key and associated challenge to 
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optimally exploiting the diversity of data available, however, is in integrating 
breast cancer microarray samples from different microarray platforms and study 
population. Studies have shown that increased sample numbers and diversity 
should increase statistical power and discovery of population-independent 
predictive signatures (Nevins et al., 2003; Rung & Brazma, 2013). In the current 
era, the advent of large-scale next-generation sequencing, and the advantages of 
RNA-Seq in complete cancer transcriptomic profiling, holds immense promise for 
more accurate diagnostic and prognostic signature discovery (Cieślik & 
Chinnaiyan, 2018).  
Prognostic and predictive gene signatures like Mammaprint™ and Oncotype 
DX™ (Buyse et al., 2006; Toole, Kidwell, & Van Poznak, 2014), using gene 
expression profiling with large microarray datasets indicates that gene-expression 
profiling has great potential for improving breast cancer management and 
increasing our understanding of disease biology. To date, only one clinically 
available gene signature is available developed using RNA-Seq data, 
FoundationOne Heme (Doebele et al., 2015), and focuses on gene fusion detection 
in soft tissue sarcomas (Byron et al., 2016).  
Machine learning has been broadly applied to building breast cancer classifiers 
from gene expression data (Yue, Wang, Chen, Payne, & Liu, 2018). The 
simplicity of the Gene Expression Barcode (GExB), allows the integration of data 
from a diversity of experiments to develop accurate classifiers using machine 
learning algorithms. The absolute measures of expression, 1's and 0's, generated 
by the GExB, make implementation of a filter feature selection technique 
attractive; setting parameters for relevant variable (gene/probe) identification of 
differentiating features between diseased and healthy breast tissues. Applying 
these features to sophisticated algorithms, like SVM, holds promise for 
identifying robust and accurate gene signatures and the absence-presence nature 
of the signals would allow any finding to be easily migrated to simpler technology 
platforms such as RT-PCR. 
1.8 Aims and Objectives 
This study was split into two parts: 1) The application of the GExB to Micro-array 
data and 2) The development of a barcoding method for RNA-sequencing data, 
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comparable to the GExB algorithm 
 
1.8.1 The application of the GExB to Micro-array data 
Hypothesis: Integrating existing breast cancer microarray expression data using 
the Gene Expression Barcode concept will enable the discovery of easily 
assayable signatures for classifying breast cancer samples into subtypes. 
Main aim: Develop a feature selection method to identify predictive signatures in 
simplified expression datasets and test classification accuracy on “real” clinical 
datasets. 
The following objectives were identified for achieving the main aim: 
(1)  Production of gene expression barcodes for breast cancer subtypes and 
development of a method for integrating barcodes from different chips.  
(2)  Development of an automated feature selection pipeline for identifying a 
minimal set of expression features based on (1). 
(3)  Evaluation and optimisation of the feature-selection method using a simple 
classifier. 
(4)  Derivation of a variation of the feature-selection method for development 
of a multi-class classifier. 
 
1.8.2 The development of a barcoding method for RNA-sequencing data, 
comparable to the GExB algorithm 
Main aim: To discover a novel method to convert gene counts in RNA-Seq data to 
absolute calls of expression, i.e. 1's and 0's, and therefore creating a “barcoding” 
method for NGS data 
Objectives: 
(1) Development of a method for barcoding RNA-Seq data and application 
on breast cancer data from The Cancer Genome Atlas (TCGA) 
(2) Development of a two-class classifier for TCGA normal and tumour 
samples with feature selection based on best differentially expressed 
genes 
(3) Integration of RNA-Seq data from normal breast tissue samples, from 
the Genotype-Tissue Expression (GTEx) project to discover a 
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signature for multi-class classification capable of distinguishing 
between normal, normal-from-cancer-patient, and primary tumour 
samples. 
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Chapter 2 
A Two-Class Breast Cancer Classifier for Malignancy 
 
ABSTRACT 
INTRODUCTION: 
Breast cancer is a heterogeneous disease with an ever-growing increase in the 
biological subtypes being recognized. Along with molecular subtypes, are 
metastatic and primary cancers, where molecular profile, tumour histology and 
grade collectively contribute to subtype diversity.  Accurate subtype classification 
has been shown to coincide with improved diagnosis, prognosis and aetiology; 
imparting a comprehensive patient status with strong correlation to clinical and 5-
year survival outcomes. Histopathological examinations of tumours, which are 
mostly inaccurate, is unfortunately still the classification method of choice. 
The use of gene expression profiling has been studied extensively for 
implementation in breast cancer subtyping. These profiles include classification, 
prognosis and in the case of MammaPrint™, chemotherapy sensitivity, and breast 
cancer recurrence with Oncotype DX™. Despite the success of MammaPrint™ 
and Oncotype™ DX, significant advances in diagnosis and treatment by gene 
expression profiling, diagnostic gene signatures need to be further explored. 
The Gene Expression Barcode was developed to overcome the constraints of 
microarray expression data, such as probe effects, noisy data and the relationship 
between intensity and actual expression. The algorithm shows clear demarcation 
of low and high expression measurements to classify genes as silenced and 
expressed by means of a binary ‘barcode’. As signatures derived from absolute 
expression calls would simplify implementation in a laboratory setting, we 
explored the potential of expression barcodes as features for machine learning 
based classification. We present a simple method, which combines biologically 
relevant feature selection with the K-means clustering algorithm to accurately 
classify breast tissue samples as being normal or malignant.  
METHODOLOGY: 
Carefully selected and curated normal and tumour samples were obtained from 
the NCBI’s Gene Expression Omnibus database. We developed a filter to produce 
a minimal discriminating feature set/barcode by selecting probes which were 
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stably expressed within tissue types, yet differentially expressed between the two 
tissue types. K-means clustering of tissues based on the minimal feature set was 
performed to ensure that the barcode signature was able to correctly classify the 
training set. Unseen samples from both the original and unrelated experiments 
were then classified to ascertain the predictive accuracy of the signature and its 
ability to generalize to the classification of unseen samples. 
RESULTS: 
The optimized feature selection filter of binary data reduced the feature set from 
22215 to 85 informative probes. K-means clustering showed clear separation of 
normal epithelial breast tissue and primary tumour samples. A 100% accuracy in 
tissue classification was observed, even for samples from tumour classes not 
represented in the training set. 
DISCUSSION: 
With a simplistic filtering and clustering technique, we were able to classify 
unseen normal breast and tumour samples with 100% accuracy based on gene 
expression data that has been converted to ‘absence/presence calls’. We propose 
that such signatures, which may be easily translated to a PCR- or hybridization-
based laboratory test, shows promise for reliable classification of tissues of 
ambiguous malignancy status. Furthermore, we predict that pairing our barcode 
and filtering approach with more powerful classification techniques such as multi-
category support vector machines could produce robust expression-based 
classifiers that have potential for clinical application. 
 
2.1 Introduction 
The prevalence of breast cancer incidence has risen to 8 million cases globally 
between 2007 and 2015, making it the leading cause of cancer deaths among 
women internationally and in South Africa (Ferlay et al., 2015; Siegel et al., 
2012). This highlights the importance of early-detection and accurate 
classification of a biopsied tissue prior to any treatment decisions being made.  
 
2.1.1 Breast Cancer Classification 
The development of prognostic and predictive breast cancer gene expression 
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signatures has been a decade-long aim of many gene-expression profiling and 
bioinformatics studies. Diagnosing a patient with breast cancer accurately from 
the molecular portrait of the biopsy cells improves the treatment choices made for 
the patient, and also the survival outcomes (Henderson & Patek, 1998). The 
complexity of making accurate diagnostic decisions, however, lies in the 
heterogeneous nature of the disease; which is comprised of distinct subtypes 
having varied clinical, pathological and molecular presentations. Initial diagnosis 
of breast cancer heavily relies upon histopathology examination of biopsied 
tissues; immunohistochemical (IHC) staining of biopsied cells which reveal the 
presence or expression of hormone receptors estrogen, progesterone and human 
epidermal growth factor 2 (Her2) (Patnayak et al., 2015). However, these 
examinations are poorly reproduced for a given breast cancer case, and thus 
cannot always be relied upon as informative enough for clinicians to make a 
diagnosis (Haibe-Kains, 2010). In a recent study on the reliability of IHC 
examinations, 83% of the molecular subtypes were shown to be misinterpreted 
(Jorns, Healy, & Zhao, 2013). This demonstrates that even though IHC in terms of 
hormone receptor presence is reliable, misinterpretation still negatively impacts 
the treatment decisions of clinicians, with far-reaching consequences.  
 
2.1.2 Gene Expression Profiling 
Advances in microarray technology have granted biologists the ability to measure 
and assess the expression levels of thousands of genes in a single assay. Using the 
data and knowledge obtained, the discovery of molecular breast cancer subtypes 
has emerged. Gene expression profiling has been used to develop clinically 
relevant and implemented signatures for diagnostics and prognostics (Sotiriou & 
Piccart, 2007). The development of predictive and prognostic gene signatures 
such as Mammaprint™ has assisted clinicians with informed treatment decisions. 
Mammaprint™ is a 70-gene signature predictor of chemotherapy sensitivity of a 
patient. This clinical assay however has limitations in application, as only 
adjuvant drug therapy choices and consequent treatment course decisions, are 
informed. Oncotype DX™ is a PCR assay used in breast cancer prognostics; 
consisting of a 21-gene signature, which assigns a score for the likelihood of 
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recurrence of breast cancer in lymph-node negative, estrogen-positive patients. 
The assay is however limited to application in estrogen-positive breast cancer 
subtype cases (Toole et al., 2014). Despite the efforts of molecular biologists and 
bioinformaticians to discover a generically, globally applicable gene expression 
assay which can assess the multiple facets of the disease, the constraints of using 
traditional microarray raw data analysis has impacted the discovery of such 
signatures (Nevins et al., 2003).  
 
2.1.3 Microarray Data Analysis simplified with The Gene Expression 
Barcode (GExB) algorithm 
The development of Frozen Robust Microarray Analysis (fRMA) and the Gene 
Expression Barcode (GExB) has addressed the difficulty in using integrated 
microarray data from different experimental cohorts and different micro-chip 
platforms to generate molecular profiles of tissues (McCall et al., 2011). Robust 
Microarray Analysis (RMA), a broadly used normalization tool for raw data, is 
restricted to application of the experiment set under investigation (Irizarry, Hobbs, 
et al., 2003). Normalization parameters and threshold values for assigning up- or 
down-regulation of genes’ expression are relative measures across the microchip 
signals being interpreted (McCall et al., 2011). fRMA conversely, has 
precomputed generalised values, from thousands of microarray samples, for data 
normalization, which allows raw data to be preprocessed identically. The meta-
analysis of healthy and diseased tissues of the body has standardized parameters 
that mitigate the clouding factors of gene expression level values; probe effects, 
mismatched probes, noisy data(McCall, Bolstad, & Irizarry, 2010b). The GExB 
algorithm takes this continuous data, i.e. expression values, and assigns an 
absolute measure of gene presence or absence, represented by a “1” or “0” 
respectively (McCall et al., 2011; Zilliox & Irizarry, 2007b). The resultant 
sequence, or barcode, is similar to the Affymetrix MAS 5.0 absent-present 
algorithm, but is more robust and not limited to a single experiment set due to the 
fRMA preprocessing phase.  
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2.1.4 Feature Selection for Classification 
Beyond the analysis of continuous data is discovering genes and/or microarray 
probes that are informative as distinct features to separate subtypes of a tissue. 
Feature selection is an integral part of designing a classifier; predominantly paired 
with a machine-learning algorithm. K-means clustering, an unsupervised 
clustering algorithm and Support Vector Machines (SVM) paired with feature-
selection has proven to build efficient and accurate classifiers. SVM in particular 
has been used in classification systems for medical diagnosis (Akay, 2009). The 
success of the SVM, however, relies upon an optimal feature set and training 
dataset size. Finding a balance between informative features, microarray probes in 
this instance, and too many restrictions is key to avoid an overfitted classification 
model, which is still accurate (Domingos & Pedro, 2012). 
 
2.1.5 Study Aims and Objectives 
We therefore propose an integrated approach to develop a two-class signature that 
can accurately distinguish healthy breast tissue from malignant breast tumours, as 
a way to assess the utility of expression barcodes in tissue classification, and as a 
step towards developing a multi-class classifier. Public biomedical databases 
contain millions of dollars’ worth of potentially reusable gene expression data that 
can be used to derive novel biological insights or to develop predictive 
diagnostics. The key lies in integrating and normalizing data from different 
technology platforms to make them comparable. Increased sample numbers and 
diversity is expected to increase statistical power and discovery of population-
independent predictive signatures. The GExB data transformation procedure 
allows data integration, since data from different chip platforms is made 
numerically comparable. Feature selection is also simplified due to absolute calls 
being compared versus continuous data i.e. relative expression. Provided the 
feature set is small enough, the simplicity of “on/off” expression signals of the 
GExB allows any identified signature to be easily migrated to and assayed on 
simpler technology platforms such as real-time multiplex PCR. 
 
We hypothesized that integrating existing breast cancer microarray expression 
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data using the Gene Expression Barcode concept will enable the discovery of 
easily assayable signatures for classifying breast cancer samples into subtypes. 
Our main aims included: 
1) Developing a method for integrating barcodes from different 
Affymetrix chips/platforms into a 'meta-dataset' with as many 
samples as possible.  
2) Developing a feature selection pipeline for identifying a minimal 
set of discriminating expression features based on (1).  
3) Producing gene expression signatures for normal and cancer breast 
tissue types  
4) Development of a variation of the optimized feature-selection 
method for multi-class classification. 
 
2.2 Methods and Materials 
2.2.1 Data Curation 
In order to build large and diverse training and test datasets with machine learning 
algorithms, data integration was imperative. Integrated datasets not only offer 
biological diversity to the classifier, but improves the likelihood of discovering 
informative microarray probe sets that can be generically applied to any of the 
Human Genome Array platforms and to many population groups.  
 
During data collection from the Gene Expression Omnibus (GEO) repository, 
labelled samples were hand-curated. The GEO annotation of the sample file was 
very important, as the initial classification of the tissue has to be reliable in order 
to assemble a training set which was accurate and biologically correct. In 
particular, the healthy breast tissue samples were collected from cancer-free 
patients, so as to ascertain a true molecular portrait of normal breast tissue. 
 
Raw micro-array data was curated from the NCBI Gene Expression Omnibus. 
Table 2.1 shows the variability of the data sources. Samples used as training data 
came from different experiment sets than data samples used for validation of the 
two-class classifier. Most notably, Her2-positive breast cancer samples were 
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obtained for validation, but were not included in the training set data and were 
instead intended to serve as a very difficult test case for the predictor. 
 
Further sample source variability was introduced by integrating data from 
different Affymetrix Human Genome Array Platforms; GPL96* ([HG-U133A] 
Affymetrix Human Genome U133A Array) and GPL570* ([HG-U133_Plus_2] 
Affymetrix Human Genome U133 Plus 2.0 Array). 
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Table 2. 1: Summary of Breast Cancer Samples curated 
Dataset Tissue Type GEO Series GEO Platform 
(Affymetrix) 
Training Normal Epithelium GSE20437 GPL96* 
Normal Duct GSE5764 GPL570* 
Normal Lobe GSE5764 GPL570 
Triple Negative Breast Tumour GSE25065 GPL96 
Estrogen-Positive Breast 
Tumour 
GSE25065 GPL96 
Primary Breast Tumour GSE2990 GPL96 
Inflammatory Breast Cancer 
Tumour 
GSE5847 GPL570 
    
Test/ 
Validation 
Normal Epithelium GSE9574 GPL96 
Triple Negative Breast Tumour GSE31519 GPL96 
Her2-Positive Breast Tumour GSE42822 GPL96 
Estrogen-Positive Breast 
Tumour 
GSE23988; 
GSE22093 
GPL96 
Primary Breast Tumour GSE21217; GSE5462 GPL96 
Inflammatory Breast Cancer 
Tumour 
GSE22597 GPL96 
*GPL96 - [HG-U133A] Affymetrix Human Genome U133A Array 
*GPL570 - [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array 
 
2.2.2 Gene Expression Barcode (GExB) implementation and data 
integration 
The raw microarray data collected was pre-processed with the fRMA algorithm. 
This ensured that the samples were identical with regard to the expression calls 
rendered from the varied experiment sources. Batches of micro-array samples 
were pre-processed according to tissue type (Normal or Tumour) and allocation to 
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either Training set or Validation/Test set.  
 
The Gene Expression Barcode (GExB) algorithm was then applied to the pre-
processed data to convert the raw expression calls rendered from the micro-array 
chips to an absolute call for probe, 1 or 0. Figure 1 shows how the algorithm 
converts the raw data to a barcoded sequence for each sample. The data from 
different platforms were then merged/integrated so as to form a training set of 
each tissue type with only absolute calls, a 1 or a 0 to represent the absence or 
presence of a gene expressed.  
  
 
Figure 2.1: Example of expression calls from a micro-array (left side) converted to an 
absolute call of gene expression (right side) by use of the Gene Expression Barcode 
algorithm. 
 
2.2.3 Feature selection 
Feature selection was the first step in the protocol towards finding informative 
probes that reliably discriminate normal breast tissue from tumour (malignant) 
tissues. Using the GExB algorithm, along with a filter-feature selection approach, 
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the discovery of informative probes was a two-step method. 
 
Phase I: Signature discovery 
To ascertain if the approach validity for further exploration, 30 samples per tissue 
subtype, 60 in total were used as the training set. Criteria for filtering included: 
1) 90% stable expression of a gene/probe within each tissue type (1 or 0) and;  
2) Differential expression between the two tissue types, e.g. “1” in class A 
and “0” in class B.  
 
60 unseen samples for every subtype within the two classes was used to validate 
whether the features selected were informative. 
Phase II: Method Optimization 
Once the results from Phase I proved the GExB-FS method capable of producing 
an informative probe set that could accurately discriminate between normal and 
tumour breast tissue samples, the next step was to optimize the informative probe 
set with a larger training data set. Feature selection required the criteria of the 
filter criteria to be adjusted. The training set now included 100 samples, 50 
samples per tissue subtype, and 120 unseen test samples for validation of the two-
class classifier. The main differences included: 
1) 85% stability of a probe being absent or present in a tissue subtype; 
2) Differential expression between subtypes; present (“1”) in class and absent 
(“0”) in class B or vice versa. 
 
When the samples numbers were increased for the training set, the 90% stability 
parameter applied in Phase I proved restrictive, and too few informative probes 
were produced. Thus, the within-class stability was lowered to allow for slight 
variability in expression of genes/probes, yet still yielding a small and informative 
probe set capable of discriminating between the tissue subtypes. Although the 
second criteria remained the same with regard to differential expression between 
the subtypes, due to the variability of probe presence/absence permitted by the 
85% stability parameter, the new features discovered would add a new dimension 
to how informative the probes selected would be by: 
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1) Probe “expressed” in A and “not-expressed” in B; or 
2) Probe “expressed” in B and “not-expressed” in A; or 
3) Probe “expressed” in A and “unstable” in B, and vice versa 
 
2.2.4 Machine learning classifier based evaluation of the signatures 
Machine learning algorithms were used to evaluate the ability of the features 
selected to successfully discriminate between healthy/normal and 
tumour/malignant breast tissues.  
 
2.2.4.1 K-means and Hierarchical clustering 
K-means clustering was employed as an initial unsupervised machine learning 
algorithm (performed with R, and visualized in RStudio) to assess if the 
feature selected to separate the tissue types into two clusters successfully. The 
algorithm was run at 1000 iterations for both the preliminary and final training 
sets. Hierarchical clustering (performed with R, and visualized in RStudio) 
was employed consequently to visualize how the samples were classified 
based on their relation to each other, i.e. how similar the barcodes of each 
sample were to one another, and if based upon these similarities within a class, 
could be separated from another class. This part of classifier design was part 
of the initial validation of the feature selection paired GExB protocol. 
 
2.2.4.2 Support Vector Machines (SVM) 
Subsequent to K-means clustering, the robustness of the features selected was 
further evaluated using a more sophisticated machine learning algorithm, in 
this case SVM. The e1071 R package, which contains libraries for support 
vector machines (libsvm), was implemented. The training sets were used to 
train the machine to recognise a sample based on the pattern of probe absence 
or presence within a tissue subtype. Validation of the predictive capacity of 
the features selected was completed with unseen samples. Additionally, 
samples of a malignant breast tissue subtype not included in the training sets 
was also tested on the classifier, as a very difficult test case not usually 
performed in such research. 
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2.3 Results 
2.3.1 Phase I: Preliminary Method Design 
2.3.1.1 Gene Expression Barcode-Feature Selection paired method (GExB-
FS) 
The filter approach to selecting features using the barcode processed samples 
produced 64 informative probes. The 90% stability parameter was strict 
enough to rule out excessive variability between samples of the same tissue 
type. Differential expression analysis proved that there are definite differences 
of gene expression in diseased tissue compared to healthy tissue. The filter 
applied minimised the data significantly – from more than 22000 probes to 
just 64 informative probes. Reducing the high dimensionality of the data was 
achieved as less than 1% of the original data was used to discriminate between 
breast tissue subtypes. 
 
2.3.1.2 Machine Learning: K-means, Hierarchical clustering, SVM 
The dendogram in Figure 2.2 shows a clear separation of Normal from 
Tumour breast tissue using the 64 informative probes. The two distinct 
branches within the dendogram illustrate the robustness of the feature 
selection method applied alongside the GExB protocol in identifying probe 
signatures that can discriminate between tissue 
types.
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Figure 2. 1: Hierarchical clustering of Training Data Set using 64 informative probe set 
 
Validation of the two-class classifier was confirmed when unseen samples were 
tested alongside the training data. Table 2.2 shows that both K-means clustering 
and SVM had a high classification accuracy of 95% and 100% respectively. Most 
notable was the unseen subtype of breast cancer, Her2-positive, which despite not 
being part of the training set, classified 100% accurately with the rest of the breast 
cancer samples. 
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Table 2. 2: Validation of Preliminary Two-class Classifier 
Tissue Type No. samples 
tested 
Classification 
accuracy 
(K-means) 
Classification 
accuracy 
 (with SVM) 
Normal 10 100% 100% 
Primary Tumour 10 100% 100% 
Estrogen Receptor 
Positive 
10 100% 100% 
Triple Negative 10 80% 100% 
Inflammatory Breast 
Cancer 
10 90% 100% 
Her2-positive 10 100% 100% 
Total: 60 95% 100% 
 
2.3.2 Phase II: Method Optimization 
2.3.2.1 Gene Expression Barcode-Feature Selection paired method (GExB-
FS) 
From the results obtained in the preliminary phase, the classifier was further 
developed to ensure true validity and to assess the generic nature of the feature 
selection GExB paired method. However, when samples numbers were increased 
within the training set, the initial 90% stability (of gene expressed/unexpressed) 
parameter became restrictive. Too few informative probes were rendered to 
clearly demarcate tissue subtypes. 
 
When the stability parameter was lowered to 85%, 85 informative probes 
remained after filtering. The lowered criteria did not compromise on the stable 
absence or presence of expression of a gene, but did permit slight variability of 
expression to be included. The new parameters brought about a new dimension to 
the features selected. An additional criterion was introduced to feature selection 
during method optimization. The differential expression of probes was no longer 
limited to the scenario of “on” in class A and “off” in class B, but allowed for a 
stable-but-varied expression measure to be introduced. Within a larger dataset, 
tumour heterogeneity would factor in, due to tumour stages and grading, and 
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molecular subtype. Lowering the stability criteria to 85% allowed probes which 
had a slight variance (15%) in expression due to the mixed nature of the samples 
within this study, to still be considered as the general up- or down-regulation of 
that gene. Probes which were expressed or not expressed less than 90% of the 
time were previously excluded in Phase I, lowering the stability cut-off parameter 
allowed a more informative probe set to be produced during Phase II.  
 
2.3.2.2 Machine Learning: K-means, Hierarchical clustering, SVM 
Figure 2.3 showed that when hierarchical clustering was applied to the data 
subsequent to K-means clustering, a clear separation of tissue types was clear. The 
dendogram illustrates that the new parameters gave similarly high-accuracy 
results to that of the preliminary phase. 
 
Figure 2. 2: Hierarchical clustering of Training Data Set using 85 informative probe set 
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Unseen data confirmed that the selected probe signature was robust and 
informative enough to enable exceptionally accurate classifications. The accuracy 
of the two-class classifier with K-means clustering improved from 95%, in the 
preliminary phase, to 100% (Table 2.3). Both K-means and SVM classified 
unseen microarray samples 100% accurately. The Her2-positive breast cancer 
samples, not initially part of the training set, classified 100% accurately again. 
 
The new minimised 85 informative probe set thus proved to improve the accuracy 
of the two-class classifier with regard to both K-means and SVM classification. 
The improved accuracy could be attributed to the optimised probe set being more 
informative as it allowed for previously excluded probes which were not always 
present or absent in 90% of samples, but were discriminative between the two 
breast tissue subtypes. 
Table 2. 3: Validation of Optimized Two-class Classifier 
Tissue Type Classification accuracy 
(K-means) 
n = 10 
Classification accuracy 
 (with SVM) 
n = 20 
Normal 100% 100% 
Primary Tumour 100% 100% 
Estrogen Receptor Positive 100% 100% 
Triple Negative 100% 100% 
Inflammatory Breast 
Cancer 
100% 100% 
Her2-positive 100% 100% 
Total: 100% 100% 
 
2.4 Discussion 
GExB-FS method showed significant promise for classification with a small 
dataset. 
The results yielded in the preliminary phase proved that the Gene Expression 
Barcode (GExB) shows promise in classification, even when using a small 
training dataset. The binary expression measures simplified feature selection of 
informative probes that could reliably separate the healthy/normal breast cancer 
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samples from the malignant samples. When implementing a simple filter based 
purely on the stability of a probe's presence, a 1 or a 0 as allocated by the GExB 
algorithm, the features found do not require further analyses. This is due to 
biological and pathological relevance of the genes linked to the probes not being 
taken into account to avoid assumptions that may prematurely discard relevant 
features. The criteria for filtering raw microarray data to discover an informative 
feature set by minimisation of probes thus did not include biological measures; 
and the association of a probes to genes involved in disease, cancer, known 
biological pathways were ignored. Instead, the filter criteria purely selected for 
parameters related to stable expression and differential expression. In so doing, 
the informative probe set may include genes not yet associated with breast cancer, 
cancer, apoptosis or any of the known malignancy pathways. Thus, unknown 
genes may also be included in the informative feature set which would ordinarily 
be excluded. While not the aim of this study, these genes could be further 
explored as potentially being involved in tumorigenesis. 
 
Method optimization justified by preliminary phase results 
The credibility of the GExB-FS method applied to a machine learning training set 
has been proven by the results rendered from validation testing with both SVM 
and K-means algorithms. The SVM algorithm, originally designed to solve binary 
classification problems outperformed the K-means clustering algorithm trained 
with the same data and tested with the same validation set. The true measure of 
the protocol design was in testing the machine-learning algorithms with 
completely unseen samples in the form of Her2-positive breast cancer tissue, i.e. 
not part of the training tumour set at all. Surprisingly, both K-means and SVM 
classified the Her2-positive class as malignant with 100% accuracy, and SVM 
performed with 100% accuracy for all tissue types. 
 
The compelling results of the preliminary phase gave justification towards further 
developing and optimizing the discovery of a barcode signature that could classify 
a tissue as healthy or malignant with a larger data set. Research has shown that 
larger datasets, trimmed with informative feature sets and  applied to sophisticated 
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machine learning algorithms like SVMs produce more robust predictive gene 
signatures (Domingos & Hulten, 2003; Domingos & Pedro, 2012). 
 
Larger training set improves classification 
The positive effect of training a machine-learning algorithm with a larger dataset 
was illustrated when comparing Tables 2.2 and 2.3. The larger dataset yielded 
100% accuracy for both the unsupervised and supervised machine-learning 
algorithms, proving that the features selected were informative in that they were 
distinctive to which genes are differently expressed between healthy and tumour 
tissues.  
 
The improved accuracy of the two-class classifier can be partially attributed to 
two main differences in the feature-selection phase of the protocol. Firstly, the 
stability parameters were lowered to 85%, allowing variability within the 
differentiating features; although stable in “A”, varied stability in “B”, instead of 
stable in both but differential. This allowed for a more informative probe set to be 
discovered. Secondly, there are 21 more probes selected as features with the larger 
training set, and these extra probes found, offer more tissue-discrimination 
potential. This was expected, as previous insights into machine-learning imply 
that more data the algorithm has to “learn” from, the easier it is to recognise an 
instance of similarity (Domingos & Pedro, 2012). An unsupervised machine 
learning algorithms ability to correctly classify samples and discriminate between 
different classes is boosted with more samples to train from; thereby finding 
similar features between samples to form distinct data clusters.   
 
The Her2-positive breast tumour subtype, initially not part of the tumour training 
set continued to classify with 100% accuracy with both K-means clustering and 
SVM algorithms. Validation with an unseen sample and tissue subtype 
demonstrates the discriminative ability of the 85 informative probe set in correctly 
classifying healthy and malignant tissues. This strongly suggests that there is 
potential to identify and classify ambiguous breast tissue samples or apparently 
benign tumours that have as yet unexpressed malignancy potential and would 
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require higher-priority interventions. 
 
SVM accurately discriminates GExB-FS processed data  
The GExB-FS method was shown to be a reliable discriminator between healthy 
and malignant breast tissues when training data, containing only the discovered 
features, is used to train an SVM. This is due to the absolute calls made by the 
GExB algorithm. Training a sophisticated supervised machine-learning algorithm, 
like SVM, on distinct discriminative features distilled from a large training set, 
achieves two of the prerequisites for optimal machine-learning classification; 
more training examples with distinctive features allows the machine, SVM, to 
make better informed decisions (Akay, 2009). Traditional methods of differential 
gene expression analysis of microarray are largely impacted by technical variance 
in datasets, specifically of the same tissue type, in the form of noise and batch 
effects. Batch effects are caused when samples are processed in different batches, 
resulting in experimental bias linked to the array and probe fluorescence readings 
(Scherer, 2009). This has previously been shown in studies finding molecular 
signatures of breast cancer having similar aims and approaches but yielding 
different outcomes despite using  machine learning algorithms for classification 
(Ransohoff, 2005). The GExB algorithm addresses these biases as samples are 
preprocessed with fRMA, and barcoding may be executed on single samples, or 
for batches. Integration of samples from different platforms, and experiments is 
possible through comparative gene expression calls in the form of 1’s and 0’s.  
 
GExB-FS method is reproducible 
Data integration is complex due to experiment cohorts utilizing different raw data 
preprocessing methods; i.e. Robust Microarray Analysis (RMA), Log2 intensities, 
Affymetrix MAS 5.0 Suite. Improving classification models and deriving gene 
expression signatures that are robust and accurate, however, relies upon data 
integration. The 85 informative probe set was developed by integrating raw 
microarray data from 5 experiment sets and validated with data from 8 experiment 
sets. To ensure data comparability, the data had to be processed identically (Table 
2.1). As the GExB uses Frozen Robust Microarray Analysis (fRMA) to normalize 
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and pre-process data, this in itself ensures that each sample used it processed 
identically, regardless of which original experiment it was used in, and the data 
normalization method initially used. Thus, the GExB calls related to absence and 
presence are not only reproducible, but also integrative. The SVM can thus be 
trained on a diversity of samples and be validated by unseen samples, including 
those not included in the initial training set. 
 
2.5 Conclusion 
By applying a novel paired method, the Gene Expression Barcode and Feature 
Selection (GExB-FS method), data from 13 different Affymetrix experiment sets 
processed 2 different chip platforms. The result was a set of more than 300 
samples integrated to develop a two-class breast tissue classifier. Application of 
the GExB-FS led to the discovery of a minimised feature set which accurately 
discriminated between healthy and malignant breast tissue samples. An 85 
informative probe set was produced as a signature for breast tissue subtype 
classification, with 100% accuracy. 
 
The implications for such a reliable signature, is ease of translation into a simple 
laboratory testing protocol, such as RT-PCR. The small feature set, 85 probes, can 
also be assayed on a standard 96-well PCR plate, without the expense or 
complications of designing a new technology. Absolute calls, absence and 
presence of a probe or gene expressed, are much easier to assess and implement in 
a laboratory set up. Moreover, the importance of being able to classify a sample as 
malignant or normal is crucial in identifying cancers, since tissues may look 
normal according to microscopic and histopathological studies, but may in fact be 
cancerous (K. Graham et al., 2010). Clear and accurate classification of a tissue is 
the first step towards an accurate and informative diagnosis. 
 
We have shown in this chapter that the GExB-FS method has the potential for use 
in developing a multi-class breast cancer classifier. As the method could identify 
discriminating features between healthy and diseased tissues with as yet 
unprecedented accuracy, it thus may be able to identify features that separate 
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multiple subtypes of a disease, which is the primary aim of the next chapter. 
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Chapter 3 
A Multi-Class Breast Cancer Classifier for Molecular Subtyping 
 
ABSTRACT 
INTRODUCTION: The Gene Expression Barcode (GExB) method, which 
converts continuous expression levels into binary calls signifying genes as 
silenced or expressed, was previously employed as a way to enable integration of 
data from multiple experiments and across chip platforms for the purposes of 
machine-learning based classification of tumour samples. In combination with a 
simplistic feature selection method, a gene signature for the identification of 
malignant breast tissue samples was discovered in Chapter 2. Following the 100% 
accuracy of our two-class classifier for identification of healthy and/or malignant 
breast tissue, we explored whether our GExB + Feature Selection (GExB-FS) 
approach can be used to develop a multi-class classifier for breast cancer 
subtyping. 
METHODOLOGY: We implemented a multi-class feature selection variation and 
tested it on samples from normal and several subtypes of malignant tumours. The 
85-90% stability criteria was adjusted to 80% stable in n-1 subtypes to identify a 
signature which could accurately classify healthy breast tissue and three molecular 
subtypes; Estrogen-Positive, Her2-Positive, and Triple Negative. The training set 
for the optimized multi-class classifier included 200 samples, with 80 samples for 
validation with k-Nearest Neighbour (kNN) and multi-class Support Vector 
Machines (MC-SVM).  
RESULTS: The feature-selection filter yielded an expression barcode of 346 
probes, which enabled clear separation of malignant breast tumour subtypes and 
unseen samples from entirely different origin than the training set, and classified 
with 90% accuracy using simple K-means clustering. Optimized classifier 
development, with implementation of the 346 –gene signature, classified unseen 
samples with 96% accuracy (MC-SVM).  
DISCUSSION: The generated binary calls enabled us to develop a simple yet 
biologically-relevant feature selection/minimization method that simultaneously 
addressed the 'curse of dimensionality' and the sparsity of training samples, which 
are significant problems when using microarray data in machine-learning 
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applications. The ability of the GExB-FS approach to enable identification of 
signatures able to discriminate between breast cancer subtypes is illustrated with 
the high accuracy of MC-SVM classification results. We were able to derive an 
optimized variation of the feature selection method applied in two-class 
classification to identify a gene/probe signature capable of reliably classifying 
molecular breast cancer subtypes. While the 346 probe set can be probably be 
further trimmed to a much smaller core feature set, which was beyond the scope 
of this study, it would still be easy to implement the signatures on a mini-array or 
in a PCR array. This would enable, for example, assessment of the clinical 
validity in a trial across multiple population groups and of its potential for further 
development into “real-world” applications. 
 
3.1 Introduction 
3.1.1 Breast Cancer and Personalized Medicine 
The accurate classification of breast cancer greatly improves the survival 
outcomes of the patient. Correct diagnosis and insights into prognosis allow 
the clinicians to make informed decisions regarding treatment and tumour 
resection (Olopade, Grushko, Nanda, & Huo, 2008). Diagnostics and 
prognostics based on the molecular and gene expression profile of breast 
cancer subtypes translates into personalized cancer treatment. Personalized 
medicine greatly enhances the survival of the patient as treatments are tailored 
to the disease case presented (S.-H. Cho, Jeon, & Kim, 2012).  
 
The classification of a breast cancer tumour varies on molecular, 
pathophysiology and clinical presentation of the disease. The cancer in itself 
can be either in situ (localized) or metastatic (spreading) in nature and can also 
be a primary, originating in the breast tissue, or secondary to another cancer 
site. Underlying biology of the tumour includes: tumour size, lymph node 
involvement & lymphovascular invasion, tumour grade. Molecular status, 
related to hormone receptor expression is the basis of molecular subtyping of 
breast cancer, namely, estrogen receptor (ER+), human epidermal growth 
factor receptor 2 (HER2), and Triple Negative which does not express 
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estrogen, progesterone or HER2 receptors (Alanko, Heinonen, Scheinin, 
Tolppanen, & Vihko, 1985; Chia et al., 2012; Kennecke et al., 2010). 
 
The variation in hormone receptor status of breast cancer molecular subtypes 
indicates a difference in gene expression of proteins (hormone receptors) 
involved in the pathophysiology of the cancer subtypes. Studies aimed at 
assessing the expression of hormone receptors, estrogen, progesterone, and 
human epidermal growth factor (Her2), has led to gene expression profiling of 
breast cancer molecular subtypes (Kapp et al., 2006; Perou et al., 2000). In a 
2008 study, gene expression data obtained either from cDNA or mRNA 
microarray chips was processed and analysed to ascertain if a pattern of gene 
expression, a signature exists for a specific breast cancer subtype and can be 
used a predictive measure for breast cancer diagnostics. Through integrating 
previously identified subtype signatures, they discovered that subtype 
prediction and prognosis were linked (Wirapati et al., 2008).  
 
MammaPrint™ and Oncotype DX are two prognostic gene expression 
signatures which have been implemented in breast cancer diagnosis. 
MammaPrint™ is a 70-gene signature, developed on Agilent microarray data 
which classifies a patient as chemotherapy suitable or unsuitable. The 70-gene 
signature was validated with the MINDACT trial, the signature is able to 
assess chemotherapy sensitivity with genes associated with disease outcome 
and distant metastasis within 5 years (Mook, Van’t Veer, Rutgers, Piccart-
Gebhart, & Cardoso, 2007). The limitations of this signature include that the 
tumour tested needs to be a stage I or II cancer with no lymph node or 
metastases involved (Buyse et al., 2006). The Oncotype DX 21-gene signature 
assesses the prognosis of ER+ and DCIS (ductal carcinoma in situ) using a 
recurrence score on RT-PCR data (Toole et al., 2014). These two clinically 
implemented gene signatures, which predict the prognostic outcome of a 
patient with breast cancer and allow clinicians to make a more holistic 
diagnosis and informed treatment decisions (Marchionni et al., 2008; Sotiriou 
& Piccart, 2007). The same principle has been applied to other cancers 
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including prostate and colon cancers (Cruz & Wishart, 2006).  
 
3.1.2  Multi-class Classification and predictive modelling 
Due to population genetics and dynamics, epigenetics and different breast 
cancer stages, validated breast cancer subtypes present with variable gene 
expression profiles within a particular subtype. Thus tumour subtype 
classifiers need to be as generically applicable as possible (Burrell, 
McGranahan, Bartek, & Swanton, 2013). Multi-class cancer classification 
based on molecular subtypes is vastly complex due to the predominant 
difference between the subtypes being hormone receptor expression. 
Genetically, this is based on the differential expression of a small set of genes 
and can make the discovery of signatures related to differential expression 
difficult. Feature selection approaches have aimed to solve the classification 
dilemma by filtering samples in a univariate manner using genes known to be 
involved in cancer pathophysiology and hormone receptor expression 
(Statnikov et al., 2005). Machine learning algorithms would then be used to 
confirm predictive capability of the signatures identified. Although the 
identification of clinically applicative gene signatures have been successful, 
these have been shown to be limited in application and population dependent, 
and are not generically applicable due to lack of data diversity (Creighton et 
al., 2006). 
 
The analysis of gene expression data from cDNA and mRNA microarray 
experiments has led to class discovery in cancers (Golub et al., 1999) and 
subsequent subtype classification of leukaemia and other cancers. A classifier 
for leukaemia genetic subtype classification, based on classes identified by 
Golub and colleagues, was developed by applying an intrinsic gene set for 
feature selection and classification with the k-Nearest Neighbours algorithm 
(Andersson et al., 2007). Advances made in breast cancer subtype 
identification (Perou et al., 2000) and validation (Sorlie et al., 2003) has led to 
hierarchical clustering models developed for the classification of breast cancer 
based on the estrogen receptor status of a tumour (Sorlie et al., 2003).  
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3.1.3  Implementing Frozen Robust Multi-array Analysis (fRMA) and the 
Gene Expression Barcode (GExB) algorithm for microarray gene 
expression data 
Microarray data is considered to be highly dimensional (Hira & Gillies, 2015). 
Transcriptomic data generated for a single sample may include gene 
expression readings for more than 7000 genes, represented by 11 probes each 
(McCall et al., 2010b). When applied to gene expression studies to profile a 
particular tissue type or disease state, the data produced becomes exceedingly 
voluminous, given that often hundreds of samples are used in comprehensive 
transcriptomic analyses. Furthermore, expression data is continuous, and 
requires analysis of relative expression and relative differential measures. 
Studies based on relativity do not often perform well on other populations and 
are not easily reproduced (Haibe-Kains, 2010).  
 
The Gene Expression Barcode (GExB) algorithm, which integrates frozen 
RMA (fRMA) pre-processing of microarray data, provides an easily 
implementable solution to high-dimensional continuous microarray data. The 
ability to assign a discrete value, 1 or 0, to infer up- (“on”) or down-regulation 
(“off”) simplifies differential gene expression analysis for classification of 
biological samples (McCall et al., 2014).   
 
3.1.4 Machine Learning and Feature selection for Breast Cancer 
Classification 
Machine learning algorithms have been extensively used in research studies to 
develop breast cancer multi-class classifiers and discovery of gene expression 
signatures (Hu et al., 2006). A comparison of machine learning algorithms has 
revealed the one-versus-one (OVO) and one-versus-rest (OVR) 
implementations of multi-class SVM (MC-SVM) to be most efficient and 
accurate (Saeys et al., 2007). However as robust ML algorithms are, when 
applied to microarray data, they are still struck by the “curse of 
dimensionality” (Bolón-Canedo, Sánchez-Maroño, & Alonso-Betanzos, 
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2016). This implies that the highly-dimensional data is too complex, with too 
many similarities between biological samples for the ML algorithm to 
differentiate between, thus hampering the development of robust classifiers. 
 
In order to optimize ML-based classifiers, feature selection is employed. 
Feature selection may be defined as the process of eliminating non-relevant, 
redundant, or non-informative features in a data set (Blum & Rivest, 1992). 
Within microarray studies, this would translate to selecting genes or probes 
which are capable of differentiating between samples or tissues.  
 
Gene selection filtering, has been shown to improve the accuracy of cancer 
classification when applied to different machine learning algorithms including 
Support Vector Machines (SVM), and artificial neural networks (ANN) 
(Golub et al., 1999). The most discriminating features (informative genes or 
probes) used when training an ML algorithm, will produce the most accurate 
classifier (Libbrecht et al., 2017).  
 
3.1.5 Aims and Objectives 
Feature selection (FS) and machine learning (ML) have been paired in the 
development of classifiers for cancer, including breast cancer (Akay, 2009; Lu 
et al., 2005). As illustrated in Chapter 2, implementing fRMA for data pre-
processing and the Gene Expression Barcode (GExB) simplifies both the 
integration and filtering of data to select for easily identifiable and 
discriminatory microarray probes. The combining of this approach for feature 
selection with well-established ML algorithms capable of handling multiple 
sample categories, holds the potential for the development of a robust multi-
class breast cancer subtype classifier. 
 
The multi-class phase of this project therefore aimed to:  
1) Develop an automated feature selection pipeline for identifying a 
minimal set of expression features based on Expression Barcoded 
data from multiple tissue types. 
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2) Evaluate and optimise feature-selection method using simple 
machine learning classifier; K-means clustering, k-Nearest 
Neighbour. 
3) Produce multi-class gene expression signatures for normal breast 
tissue and carcinoma subtypes. 
4) Derive a variation of the optimized feature-selection method 
presented in Chapter 2, with Support Vector Machines (SVM), for 
breast cancer molecular subtype classification.  
 
3.2 Materials and Method 
3.2.1 Data Curation 
Raw microarray data for building a multi-class classifier was collected in a 
similar manner to the two-class classifier (Chapter 2). 320 breast tissue 
samples were curated from NCBI Gene Expression Omnibus (GEO), varying 
in experiment sets and Affymetrix microarray platforms. Samples were 
curated for the four breast tissue subtypes by collecting data from annotated 
samples, with previous immunohistochemical identification of tissue subtype, 
or hormone receptor status (Table 3.1).  
 
Most notably, in the Training dataset, the normal breast tissue set was curated 
from three different experiment sets, and the Her2-positive breast cancer 
subtype was curated from two different experiment sets. This would ensure 
diversity of data on two levels; 1) Different microarray assay platforms, and 2) 
Raw data samples from seven completely independent experiment sets for the 
Training dataset.  
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Table 3. 1: Summary of Breast Cancer Samples curated 
Dataset Tissue Type Number of 
Samples 
GEO Series GEO Platform 
(Affymetrix) 
Training Normal (Epithelium, 
Duct, Lobe) 
57 GSE20437; 
GSE5764 
GPL96*; 
GPL570* 
Triple Negative Breast 
Tumour 
50 GSE25065 GPL96 
Estrogen-Positive 
Breast Tumour 
77 GSE25065 GPL96 
Her2-Positive Breast 
Tumour 
53 GSE37946; 
GSE42822 
GPL96 
 
Test/ 
Validation 
Normal Epithelium 20 GSE9574 GPL96 
Triple Negative Breast 
Tumour 
21 GSE31519 GPL96 
Her2-Positive Breast 
Tumour 
20 GSE22597 GPL96 
Estrogen-Positive 
Breast Tumour 
22 GSE22093; 
GSE23988 
GPL96 
*GPL96 - [HG-U133A] Affymetrix Human Genome U133A Array 
*GPL570 - [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array 
 
3.2.2 Gene Expression Barcode (GExB) implementation and data 
integration 
The raw data samples were preprocessed with the fRMA algorithm prior to 
gene expression barcode generation to ensure comparability of data from 
different experiment sets and different chip platforms. Absolute calls for 
gene expression continuous values were computed for each sample in batch 
form for each breast tissue and breast cancer subtypes. Thereafter, the 
barcodes generated were merged into an integrated dataset. 
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3.2.3 Feature selection and application to datasets 
Feature selection for multi-class classification proved more complex, as 
expected, since molecular subtypes, Estrogen Positive, Her2-Positive, and 
Triple Negative are closely related. Identifying differentiating features, i.e. 
probes or genes that are differently expressed, is challenging due to the three 
molecular subtypes sharing similar core gene expression profiles.  
 
During the development of the two-class breast cancer classifier, stability 
parameters of 90% and 85% absence or presence of a probe was used as 
feature selection criteria, in Phase I and II of classifier development, 
respectively. Here, the 85-90% stability criterion was too stringent to identify 
an informative feature set containing probes which were stable (absent or 
present) and differentially expressed between all the breast cancer subtypes. 
The parameters implemented during two-class classifier development were 
therefore adjusted to address the similarities between the molecular breast 
cancer subtypes.  
 
3.2.3.1 Phase I: Preliminary Phase - Method Development 
Using a training set of 120 samples; 30 samples per breast tissue subtype, the 
following feature extraction criteria were applied: 
1) 80% expression or non-expression stability in n-1 subtypes; 
A probe would have to be either absent or present 80% of the time in at least 
3 of the 4 subtypes.  
2) Differential expression between subtypes. 
 
The 80% stable in n-1 subtypes allowed probes that were absent or present at 
stable rate in 3 subtypes, but unstable in 1 of the subtypes to be accepted as 
informative. A probe that was stable in one subtype but unstable in another 
subtype could be regarded as a feature that distinguishes the two subtypes. 
Permutations of probe presence, absence, and varied absence/presence 
allowed an informative probe set to be identified that could separate subtypes 
from one another.  This signature was then applied to filter the barcoded 
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training and test sample data.  
 
3.2.3.2 Phase II: Method Optimization 
During Phase II, the training set was increased to include 200 samples, 50 
samples per tissue subtype. Feature selection with a larger training set, using 
the same stability parameters of 80% in n-1 proved challenging due to 
extreme variability in the data. Thus the predictive performance of the initial 
346-gene signature was tested on a larger training set. 
 
During two-class classifier development, a larger training dataset produced a 
signature which improved classification accuracy from 95% to 100%; the 
more samples the learning algorithms K-means and SVM had to train on, the 
more efficiently an unseen sample could be labelled as healthy or malignant 
correctly. This motivated the application of the multi-class gene signature set 
to a larger dataset. 
 
By applying the feature set discovered with a small training set to a larger 
training and validation set we aimed to: 
1) Train the machine learning algorithms, k-Nearest Neighbour (kNN) and 
Multi-class Support Vector Machine (MC-SVM), with a larger set of data 
samples which would, 
2) Provide the learning algorithms with a more heterogeneous gene 
expression barcode profile for each subtype. 
 
3.2.4 Machine Learning classifier evaluation 
Three different machine learning methods were used to assess the ability of 
the gene signature to successfully separate four different breast tissue 
subtypes. The test dataset included 10 samples per subtype, 40 samples in 
total, for Phase I and 20 samples per subtype, 80 samples in total, for Phase 
II.   
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3.2.5 K-means and Hierarchical clustering 
K-means and hierarchical clustering (performed with R, and visualized in 
RStudio) was applied to both the training set and validation set in Phase I 
only. The unsupervised machine learning algorithms were applied to 
ascertain an initial indication of how well the signature could cluster 
samples into their respective known breast tissue subtypes. While the K-
means clustering algorithm was initially applied to the larger set; however 
known constraints within the algorithm (Raykov, Boukouvalas, Baig, & 
Little, 2016), proved it to be unsuitable to accurately cluster the four breast 
tissue subtypes.  
 
3.2.6  k-Nearest Neighbour classification 
k-Nearest Neighbour (kNN) clustering was introduced as the initial 
machine learning algorithm to test the optimized multi-class classifier with 
the larger training set of 200 samples. kNN is a supervised instance-based 
learning algorithm, which places a sample closest to other samples that are 
similar based on the specified-identity features (Lopez de Mantaras & 
Armengol, 1998). Default kNN algorithms employ 5kNN – whereby 
Euclidean distance is used to measure the relation of a single sample to five 
other similar samples, and consequently place them in the same class 
(Coomans & Massart, 1982). Leave-Out-One Cross Validation (LOOCV) 
can be paired with kNN classification, where with each training iteration of 
algorithm, one sample is left out, which in turn verifies the correct 
allocation of a sample to its correct class (Saligan, Fernández-Martínez, de 
Andrés-Galiana, & Sonis, 2014).  
 
The chosen classification parameters were that data be separated into four 
clusters, where each sample was related to five neighbouring samples, i.e. 
data instances within that specific cluster. LOOCV was performed on the 
training set, to ascertain if the signature was robust enough to separate the 
four tissue subtypes with reasonable accuracy. 
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3.2.7 Multi-class Support Vector Machines (SVM) classification 
Although SVM was designed to solve binary classification problems, 
multi-class SVM (MC-SVM) derivatives of the algorithm exist. The two 
most commonly used algorithms being One-versus-One (OVO) and One-
versus-Rest (OVR) MC-SVM. OVO-SVM recognises each class separately 
from one another, and thus k > 2. OVR-SVM requires multiple iterations of 
a binary-SVM, with each class versus all other classes in various 
combinations.  
 
Phase I used the OVR implementation of the algorithm, to ascertain if an 
SVM trained on the signature classified unseen samples correctly. OVR 
required four iterations, as each subtype had to classify against the three 
other subtypes, i.e. four combinations of the binary SVM classifier where 
subtype A versus BCD, B versus ACD, C versus ABD and, D versus ABC. 
The OVR classifier used default parameters and tested all of the learning 
kernels: linear, radial basis function (RBF), polynomial and sigmoid. 
 
LIBSVM (Library for Support Vector Machines) (Chang & Lin, 2011) has 
a built in OVO MC-SVM module which simplified the implementation of 
the algorithm with the larger filtered dataset of 200 samples and validation 
with 80 samples. The polynomial kernel was chosen as it best fit the 
variability of the data and had previously performed well in Phase I. 
 
3.3  Results 
3.3.1  Phase I: Preliminary Method Development 
346 informative probes that could distinguish between closely related 
molecular breast cancer subtypes and healthy breast tissue, and classify 
unseen samples correctly were discovered. 
 
The dendogram in Figure 3.1 shows the clear separation of Normal and 
Tumour breast cancer samples, using the 346-gene signature. Within the 
Tumour branch, there are three nested clusters; Estrogen-Positive and Her2-
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Positive clusters branching from the Triple Negative clusters, as though two 
nested clusters are found within a larger cluster. This was expected as the 
three breast cancer tumour subtypes known to be molecularly similar.  
 
The results illustrated below reveal that signatures derived from microarray 
data transformed using the GExB-FS method to be reliable and accurate in 
multi-class classification, when filtered data is applied to unsupervised 
machine learning algorithms, like hierarchical clustering. Disease subtype 
tissues that have slight differences are successfully grouped in their own 
clusters.  
 
Figure 3. 1. : Hierarchical clustering of Training Data Set using 346-gene signature 
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During Phase I, a small set of samples was used to validate the ability of the 
346-probe set to separate tissues of four different subtypes. K-means 
clustering performed well under a multi-class scenario, with 90% accuracy. 
SVM improved the accuracy of classification, with 95% accurate 
classification of validation data. The two subtypes, Estrogen- and Her2-
Positive breast tumours, both had improved classification accuracy from 80% 
to 90%, with the implementation of the OVR MC-SVM algorithm (Table 
3.2). 
 
Table 3. 2: Validation of Preliminary Multi-class Classifier 
Tissue Type No. samples 
tested 
Classification 
accuracy 
(K-means clustering) 
Classification 
accuracy 
 (with SVM) 
Normal 10 100% 100% 
Estrogen Receptor 
Positive 
10 80% 90% 
Triple Negative 10 100% 100% 
Her2-Positive 10 80% 90% 
Total: 40 90% 95% 
 
 
3.3.2 Phase II: Method Optimization 
As K-means clustering rendered poor clustering results with the larger 
training set, Leave-Out-One Cross Validation of the kNN algorithm was 
applied to ascertain if the informative feature set was still able to accurately 
separate samples into their four respective groups. LOOCV-kNN classified 
training data with 87% accuracy. 
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Table 3. 3: kNN Leave-Out-One Cross-Validation classification of Training dataset 
Tissue Type No. samples tested Classification accuracy 
Normal 50 100% 
Estrogen Receptor Positive 50 78% 
Triple Negative 50 90% 
Her2-Positive 50 80% 
Total: 200 87% 
 
In Table 3.4, the number of unseen samples used to validate the informative 
probe set as features for a multi-class classifier, were double in comparison 
to Table 3.2. The LIBSVM implementation OVO MC-SVM was trained on 
200 samples filtered with the 346-gene signature. Multi-class SVM improved 
classification of unseen samples for the 4 breast cancer and tissue subtypes 
from 95% during the preliminary phase, to 96.25%. 
 
Table 3. 4: One-versus-one Multi-Class SVM classification of Unseen Validation dataset 
Tissue Type No. samples tested Classification accuracy 
Normal 20 100% 
Estrogen Receptor 
Positive 
20 90% 
Triple Negative 20 95% 
Her2-Positive 20 100% 
Total: 80 96.25% 
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3.4 Discussion 
Constraints of Multi-Class Classifier Development 
During the preliminary phase of the multi-class classifier development, 
discovering an informative probe set capable of clearly distinguishing 
between different breast cancer molecular subtypes (Triple Negative, Her2-
Positive and Estrogen-Positive) became a challenge. Although 
implementation of the GExB algorithm simplified the discovery of 
differentially expressed genes through generating 0's and 1's as an absolute 
measure for gene expression, the barcode expression profile of the three 
breast cancer subtypes remained largely similar.  
 
The 85% stability parameter (absent or present 85% of the time) 
implemented with two-class classification, on the basis of differential 
expression, was too restrictive to identify a large enough probe set capable of 
discriminating between four classes (three subtypes and normal) of breast 
tissue. Taking this into account, the parameters for feature-selection of 
barcoded samples were relaxed. 80% stable in n-1 subtypes satisfied two of 
the initial classification criteria of the two-class classifier, while it introduced 
an additional distinguishing criterion. Essentially, a probe was allowed to 
have varied absence or presence, below 80%, if it was absent or present 80% 
of the time in the other three subtypes/tissue types.  
 
GExB-FS method shows promise for developing a multi-class breast 
cancer classifier 
The results depicted in Figure 3.1 and Table 3.2 show that the GExB-FS 
approach, with a relaxed filtering criteria, identified 346 informative probes 
capable of discriminating four different breast tissues with 90-95% accuracy, 
despite biological and pathological relevance of the genes not being taken 
into account. This was achieved with a training set of 120 samples, 30 per 
subtype, and performance measured on a small validation set of 40 samples. 
The results obtained during this preliminary phase of classifier development, 
suggested that increasing the training data set, may yield either a more 
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discriminatory probe set, or improve the multi-class classifier accuracy. A 
larger dataset was expected to provide the learning algorithms with a 
heterogeneous portrait of the breast cancer subtypes to create a generic 
pattern against which to classify an unseen sample. 
 
Application of the feature-selection criteria to a larger dataset (n = 200), 
yielded an probe set which was not able to discriminate between the four 
classes as accurately as the initial 346 probe set, as only 79 informative 
probes were generated. This may have been due to expression profile 
similarities between the molecular subtypes, as although breast cancer 
tumours are highly heterogeneous, the intrinsic gene set which separates 
subtypes is still less than 500 genes (Perou et al., 2000). Similarly, when 
adjusting the criteria to 80% stable in n-2 subtypes, thus still permitting 
variation of stable gene expression in at least one of the four subtypes, 2518 
informative probes were identified. Although eight times the number of 
probes initially identified, the now larger feature set was too large for the 
machine learning algorithms to train effectively, and too unstable to allow 
accurate separation of different breast tissues. If a classification model's 
features are manipulated too much, the classifier becomes over fitted. 
Conversely, if the feature set is too large or too variable, the classifier is not 
discriminative enough to identify new samples accurately (Golub et al., 
1999; Sima & Dougherty, 2006).  
 
Larger training set improves classification 
The high accuracy of the multi-class classifier in the preliminary phase 
(Table 3.2) motivated further optimization with a larger training and 
validation dataset. Training a classifier on a larger dataset with limited 
discriminating features has been shown to improve the accuracy and 
reliability of a classifier (Yu & Liu, 2004). Indicated by Tables 3.3 and 3.4, 
the larger dataset, trained on the initial 346 informative probes generated in 
the preliminary phase, yielded a 87% and 96% accurate classification of 
validation samples by LOOCV kNN of the Training set and MC-SVM, 
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respectively. The signature identified in the preliminary phase thus proved to 
be robustly discriminative of multi-class data, in congruence with the theory 
that greater training data numbers yield better classification results on proven 
and validated discriminatory features (Fan & Fan, 2008).  
 
We hypothesise that finding informative feature sets that differentiate 
between two subtypes at a time, and then combining signatures non-
redundantly may be the key to discovering more informative features that 
offer more information regarding diagnostic criteria such as tumour staging 
and prognosis.  
 
Robust Gene Signature discovered with GExB-FS Approach 
The particular feature selection filter technique was applied as a model-free 
method. Feature selection was performed completely independent of the 
machine learning algorithms and ignored feature dependencies. Although 
considered a disadvantage of univariate filter models (Saeys et al., 2007), the 
approach was beneficial when developing a multi-class classifier. The 
model-free approach has been considered attractive in microarray based gene 
expression profiling, as it is less stringent than making expression-
distribution assumptions in complex biological scenarios where the 
underlying physiology is not yet fully understood  (Troyanskaya, Garber, 
Brown, Botstein, & Altman, 2002).  
 
The GExB-FS approach was able to perform with 96.25% accuracy with 
OVO MC-SVM classification. The result was beyond expectation due to the 
complexity and known difficulty of solving multi-class cancer scenarios 
where subtypes are so closely related. A previous study on multi-category 
classification methods for gene expression-based cancer diagnosis that used  
MC-SVM algorithms could not classify cancer samples above 95% accuracy 
(Statnikov et al., 2005). This proves that the GExB component of signature 
discovery has a positive effect on identifying features that strongly 
discriminate between tissue subtypes, when filtered data is classified with 
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MC-SVMs. 
3.5 Conclusion 
The feature selection and classifier development approach we employed, the 
GExB-FS method, and the validation of the discovered gene signature, with 
unseen microarray gene expression data has proven the 346-gene signature 
effective and accurate in classifying breast tissue subtypes. The probes would 
be easily translated into a laboratory test, as standard RT-PCR 384 well 
plates would be able to replicate and ascertain the absence and presence of 
transcripts. Future investigations into the overlap of the two-class and multi-
class gene signatures may allow the development a single signature capable 
of not only identifying the malignant status of a tumour, but also its the 
molecular subtype. This is already indicated by our ability to separate healthy 
breast tissue samples analysed in this chapter from the three known 
molecular breast cancer subtypes.  
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Chapter 4 
A Multi-Class Classifier for RNA-Seq Breast Cancer Data 
 
ABSTRACT 
INTRODUCTION:  
The advent of Next-Generation Sequencing (NGS) technologies has endowed 
cancer researchers with the ability to delve deeper into the genomics and 
transcriptomics governing cancer pathophysiology. RNA sequencing (RNA-Seq) 
is one such NGS platform which sequences a partial or complete transcriptome of 
a single cell or clusters of cells (tissue) and reveals the abundance and presence of 
absence of transcripts within a specific physiological state. Given the complex 
nature of breast cancer, with various molecular presentations of the disease, deep 
transcriptomic analysis allows for applications in gene expression studies, 
biomarker discovery, gene fusion and gene insertion-deletion events with 
potential to guide treatment and diagnosis.  
Projects such as The Cancer Genome Atlas and The Genotype-Tissue Expression 
project, have aimed to use RNA-Seq to comprehensively examine gene 
expression in different healthy and cancerous human tissues with their data being 
publicly available. Potential gene expression signatures have also emerged from 
these studies for breast, prostate, colorectal, ovarian and endometrial cancers, 
amongst others. 
The Gene Expression Barcode (GExB) algorithm introduced a sophisticated 
method for gene expression studies in microarray data, by assigning 1's and 0's as 
absent-present calls for genes in a sample. As demonstrated in Chapters 2 and 3, 
application of this algorithm enables successful integration of breast cancer 
microarray data originating from different studies and development of disease 
state and subtype classifiers when used alongside machine learning algorithms. 
However, no equivalent of the barcoding method exists for RNA-Seq data as yet. 
We thus aimed to develop a statistics-driven GExB-like method for RNA-Seq and 
to apply it in the discovery of a multi-class gene signature for classifying normal, 
normal-adjacent-tumour, and primary breast tumour samples from different public 
data repositories.  
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METHODOLOGY: 
We used a two-prong approach, which included first discovering highly 
differentially expressed genes (DEG's) in TCGA normal-adjacent-tumour (NAT) 
and primary tumour breast samples, as well as between normal samples from 
women that did not have breast cancer in GTEx and TCGA tumour samples. 
Secondly, in parallel, a we developed and applied “z-score-to-barcode” method to 
raw RNA-Seq gene count data to i) calculate relative gene expression levels for 
transcriptomic data, and ii) convert these values to 1's and 0's in a GExB fashion.  
Following the establishment of the methods for RNA-Seq informative gene set 
discovery and barcoding of gene count data, the study was extended to compare 
top DEG's from TCGA and integrated dataset analysis, to determine whether 
GTEx normal tissues could be classified as distinct from TCGA tumour and NAT 
samples. 
RESULTS: 
Barcoding of RNA-Seq data and application of a discovered expression signature 
enabled unseen samples in a test set to be labelled as the correct tissue type with 
above 95% accuracy when K-means clustering, Hierarchical Clustering and 
Support Vector Machines were employed for classification. In addition, we found 
that indicated that normal breast tissue from healthy women had a pattern of gene 
expression that is distinct from NAT tissues from breast cancer patients. 
DISCUSSION: 
A potentially novel and robust method for barcoding and classification of breast 
cancer RNA-Seq samples was established as demonstrated by the accuracy of the 
two-class and multi-class classifiers built using our unique approach. This method 
also has the potential to be applied to other cancers and diseases. The detection of 
a unique transcriptomic portrait of NAT tissues suggest that the similarities 
between NAT and tumour tissues and the differences between NAT and healthy-
normal tissues need to be taken into account during biomarker/diagnostic gene 
signature research. Possible insights into tumorigenesis and cancer metastases, 
along with robust discriminatory genes may be obscured or not revealed at all if 
NAT tissues are not considered a tissue subtype during cancer gene expression 
studies.  
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4.1 Introduction 
4.1.1 RNA-Sequencing and Cancer 
Next-generation sequencing (NGS) has allowed further exploration of the 
genomic and transcriptomic portraits of cells and tissues through high-
throughput DNA and RNA sequencing technologies (Ng & Kirkness, 2010). 
DNA-Seq uncovers genomic aberrations via detection of genetic lesions, 
while RNA-Seq reveals the downstream consequences of these lesions, i.e. 
mutations, nucleotide insertions and deletions, exon-skipping and gene fusion 
(M. Wan, Wang, Gao, & Sklar, 2014). RNA-Seq achieves this by taking a 
snapshot of a cell or tissue's transcriptome for a given physiological state, and 
is capable of capturing all RNA's of the cell.  
 
Transcriptomics allows for elucidation of the cellular state at the transcript 
level, and therefore the genes which are expressed or not, in a physiological 
condition. This has provided insight into those genes' involvement in a 
particular disease state (George, Ashokachandran, Paul, & Girijadevi, 2017), 
as it allows for the analysis of a continuously changing cellular environment.  
 
In recent years, optimization and reduction in costs of RNA sequencing have 
provided researchers a deeper understanding of a cell or tissue's mechanisms 
of gene expression and genetics underlying diseases (A. Desai & Jere, 2012). 
The application of NGS to various cancers, including breast cancer (Koboldt 
et al., 2012), lung adenocarcinomas (Shukla et al., 2017)), and colorectal 
cancer (Cancer Genome Atlas Network, 2012) , have revealed gene expression 
signatures not previously detected with array technologies. The verification of 
these signatures can be achieved through targeted RNA sequencing of the 
relevant transcripts (Tewhey et al., 2009). 
 
4.1.2 Breast Cancer Transcriptomics 
Breast cancer is a complex disease, with a multiplicity of clinical presentations 
differing in their histopathological and molecular portraits. The heterogeneity 
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of breast cancer, or cancer as a whole, can be attributed to differences in cell 
type origin, gene mutations, gene isoform expressed, indels, SNPs, or 
hormone receptors expressed (Turashvili & Brogi, 2017).  
 
Predictive and prognostic gene expression signatures have arisen and been 
applied clinically, e.g. Mammaprint® and Oncotype DX®, however, they 
were designed using microarrays and the resultant laboratory assays report 
expression at “gene level”. The emergence of NGS, and its application in 
cancer research, now affords researchers the opportunity to look beyond these 
established gene signatures. Transcriptome profiling of the cancer cell can 
sequence deeper to the isoform level (A. N. Desai & Jere, 2015), as well as 
detect transcripts of mRNA's, non-coding RNA's , differences in gene isoform 
expression, lending distinct advantages in understanding breast cancer 
progression, metastasis, potentially leading to better and more accurate 
classification and diagnosis.  
 
4.1.3 Public Transcriptomic Data 
Due to the biomedical advantages of RNA sequencing, coupled with the 
biological complex landscape of cancer, and understanding it’s genomic and 
transcriptomic position in relation to healthy tissues, several large projects and 
consortia arose to address these needs by producing data for analysis by the 
scientific community.   
 
4.1.4 The Cancer Genome Atlas (TCGA) 
In order to accelerate an extensive understanding of the cancer genome, The 
Cancer Genome Atlas (TCGA) was launched by the National Institute of 
Health (NIH) in 2005, with the International Cancer Genome Consortium 
(ICGC) launched in 2008 (Chin, Andersen, & Futreal, 2011). TCGA is a vast 
catalogue, containing thousands of RNA-Seq samples, with more than 30 
malignant tumour types as well as normal tissue control samples. The TCGA 
network has executed large-scale studies on breast cancer, lung 
adenocarcinoma, glioblastoma, colorectal cancer, ovarian and endometrial 
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cancer, and pan-cancer studies to fully elucidate the comprehensive molecular 
portraits of these cancers (Tomczak, Czerwińska, & Wiznerowicz, 2015).  
 
The available data types include RNA-Seq, microRNA sequencing 
(miRNAseq), DNA-Seq, SNP-based platforms, array-based DNA methylation 
sequencing, amongst others. 
 
4.1.5 The Genotype-Tissue Expression (GTEx) project 
The Genotype-Tissue Expression project was launched by the NIH in 2010. 
The aim of the project was to establish a database that would allow the study 
of differences in gene expression in human tissues (Lonsdale et al., 2013). 
Since its inception, the project has sequenced more than 10 000 samples 
(spanning 53 different tissues) from 714 donors. This in-depth analysis of 
multi-tissue transcriptomes has allowed molecular portraits for healthy or 
normal tissues to emerge, which can now aid the assessment of diseased 
tissues (Ardlie et al., 2015; Keen & Moore, 2015).   
 
4.1.6 Research Aims and Objectives 
The Gene Expression Barcode (GExB) for microarray data proved robust in 
developing a multi-class breast cancer subtype classifier. Unfortunately, since 
the release of the GExB version 3.0 in 2014 (McCall et al., 2014), a GExB 
algorithm for RNA-Seq data has not yet been developed. Owing to the 
accuracy of the microarray breast cancer classifiers developed using GExB for 
feature selection and data transformation; we aimed to develop a similarly 
applicable method for RNA-Seq breast cancer data. 
 
Aided with the differential gene expression package for RNA-Seq data, 
edgeR, we aimed to develop a simplified method for discovering a possible 
gene expression signature for breast cancer classification. In order to achieve 
this, the following objectives have been established: 
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1) Discover method to convert gene counts in RNA-Seq data to absolute 
calls of expression, i.e. 1's and 0's, and therefore creating a “barcoding” 
method for NGS data 
2) Applying the method of barcoding to RNA-Seq cancer data from The 
Cancer Genome Atlas (TCGA) 
3) Develop a two-class classifier for TCGA normal and tumour samples 
with feature selection based on best differentially expressed genes 
4) Integrate RNA-Seq normal breast tissue samples, from GTEx project to 
discover a signature for multi-class classification capable of distinguishing 
between normal, normal-from-cancer-patient, and primary tumour 
samples. 
4.2 Materials and Methods 
4.2.1 Data Curation 
RNA-Seq data (raw gene counts) from breast tissue samples from The Cancer 
Genome Atlas (TCGA) repository was manually curated. The dataset shown 
in Table 4.1 is in whole or part based upon data generated by the TCGA 
Research Network (“The Cancer Genome Atlas Program - National Cancer 
Institute,” n.d.). The individual samples were curated using their assigned 
TCGA sample ID’s from the Genomic Data Commons Data Portal (“GDC 
Data Portal,” n.d.). Individual sample ID’s may be viewed in Appendix II, 
Table 7.3. Both normal-adjacent-tumour breast and primary breast tumour 
samples were curated. The correct molecular subtypes of tumour samples 
according PAM50 classification were obtained from supplementary materials 
of a TCGA research paper (The Cancer Genome Atlas Network, 2012).  
 
For the purpose of discovering a robust set of differentially expressed genes in 
breast cancer, 40 paired normal/primary tumour samples were collected as a 
priority, but unpaired samples were also collected for downstream analysis. In 
Table 4.1, the tumour sample set in both paired and unpaired analysis 
consisted of the triple negative, estrogen-receptor positive and Her2-receptor 
positive molecular subtypes. The paired dataset was analyzed independently 
of the unpaired dataset to avoid bias in classification models. 
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Normal breast tissue RNA-Seq samples (raw gene counts) from healthy 
individuals were curated from the GTEx project’s data portal (“The Genotype-
Tissue Expression (GTEx) project Data Portal,” n.d.) on 07/13/2018, to be 
integrated with the TCGA dataset. These samples were selected from version 
7 of GTEx publicly available gene count data; which includes a total of 11688 
samples which cover 53 different tissue types. The same dataset, with patient 
information can be obtained from dbGaP (“dbGaP | phs000424.v7.p2 | 
Common Fund (CF) Genotype-Tissue Expression Project (GTEx),” n.d.). 
Individual sample ID’s may be viewed in Appendix II, Table 7.2. 
 
Table 4. 1: Summary of breast tissue samples curated from The Cancer Genome Atlas 
Data Repository 
Dataset Tissue Type Data type Data 
Repository/Project 
Paired samples Normal-Adjacent-
Tumour Breast 
Tissue 
Raw RNA-Seq 
counts 
TCGA* 
Triple Negative 
Primary Tumour 
Her2-Positive 
Primary Tumour 
Estrogen-Positive 
Primary Tumour  
 
Unpaired samples Normal-Adjacent-
Tumour Breast 
Tissue 
Raw RNA-Seq 
counts 
TCGA* 
Triple Negative 
Primary Tumour 
Her2-Positive 
Primary Tumour 
Estrogen-Positive 
Primary Tumour  
 
Integrated samples Normal (Healthy) 
Breast Tissue 
Raw RNA-Seq 
counts 
GTEx** 
* TCGA – The Cancer Genome Atlas 
** GTEx – The Genotype-Tissue Expression project 
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4.2.2 Discovery of Differentially Expressed Genes (DEGs) 
4.2.3 Paired TCGA Samples 
The R package, edgeR (Law, Alhamdoosh, Su, Smyth, & Ritchie, 2016; 
Robinson, McCarthy, & Smyth, 2010), was applied for the discovery of 
differentially expressed genes between normal and tumour samples. An initial 
set of 40 paired samples (1 normal-adjacent-tumour and 1 primary tumour 
sample from a single patient, from 20 different patients) was used. This was 
done to ensure that a differential gene expression signal was indeed present, 
and to ensure correct implementation and application of the edgeR package, 
which was central to subsequent analyses. 
 
The paired sample dataset was filtered to remove any genes which 
consistently had a zero value across both normal and tumour samples, which 
deemed ±14% of the genes to be as non-informative. Data was then 
normalized using the “upper-quartile” normalization method, allowing the 
distribution of the data to be less skewed.  
 
The generalized linear model (GLM) model, built into the edgeR package for 
more complex experimental designs of paired tissue samples, was 
implemented to identify differentially expressed genes.  
 
Once the method for discovering DEG's was established, the same protocol 
was then applied to a larger dataset: 80 paired samples – 1 normal-adjacent-
tumour and 1 primary tumour sample from 40 different patients. Although a 
slightly different output of DEG's was to be expected, the informative genes 
would later be evaluated with cluster analysis to ascertain which set of DEG's 
best discriminate between unpaired normal-adjacent-tumour and primary 
tumours. To this end, signatures representing the top 100, 75, 50, and 25 
differentially expressed genes were selected to test their ability to classify 
unpaired samples. 
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4.2.4 Integrated GTEx and TCGA datasets 
Before the edgeR package could be implemented for the discovery of DEG's 
between GTEx normal samples (from healthy individuals) and TCGA primary 
tumour samples, the RNA-Seq files needed to be comparable, considering 
their different gene library sizes. A shared gene library of 53197 genes that 
overlapped between the two different datasets was then used to filter the data 
prior to downstream analysis. 
 
A similar protocol for the discovery of DEG's was implemented for the 
integrated datasets consisting of 100 GTEx normal samples and 100 TCGA 
primary tumour samples. Trimming of zero's discarded ±6% of genes as non-
informative. The resultant DEG's were extracted and the top 100, 75, 50, and 
25 differentially expressed genes were selected for evaluation in classification. 
 
4.2.5 Separation of GTEx normal from TCGA normal-adjacent-tumour 
TCGA normal breast tissue samples are labelled as normal-adjacent-tumour 
(NAT), meaning that they are collected from patients who already have breast 
cancer. In an effort to elucidate if there were differences between normal 
breast tissue samples from healthy individuals (GTEx) versus from cancer 
patients (TCGA NAT), we extracted the top 500 and top 1000 DEG's from the 
two different DEG analysis iterations (TCGA normal versus tumour and 
GTEx normal versus TCGA tumour), and extracted the overlapping genes. 
 
This was done to ascertain if there was indeed a difference between normal 
breast tissue (from healthy individuals) and normal breast tissue (adjacent-
tumour) gene expression, and possibly discover a set of DEG's which could 
firstly characterize normal-adjacent-tumour samples, and secondly evaluate 
the ability of the discovered signature to accurately discriminate between 
normal, normal-adjacent-tumour, and primary tumour samples using a multi-
class classification. 
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4.2.6 Z-Score Barcoding of RNA-Seq count data 
Negative and positive z-scores represent normalized relative gene expression 
level, and can be used to substitute mRNA level (Siegfried et al., 2015) or raw 
HTSeq counts. In order to generate these z-scores for the normal and tumour 
RNA-Seq samples, the scale( ) command was used in R, which would convert 
raw gene counts to a z-scores within an individual sample. For each gene (of 
each sample), where the raw count of a gene (of a sample) = x, the mean of 
gene counts within that sample = mean, and standard deviation of that 
sample's gene counts = sd, then the z-scores for each gene within a sample 
could be calculated as: z = (x – mean)/sd. 
 
The extracted z-scores could thus now be 'barcoded', where a '0' would be 
assigned to a negative z-score and a '1 to a positive z-score. The ability of the 
RNA-Seq barcode to definitively classify normal and tumour samples was 
evaluated and once confirmed, could then be applied to other tissue types or 
experimental designs. 
 
4.2.7 Z-score Barcoding of unpaired TCGA and GTEx samples 
As with the TCGA paired sample dataset, RNA-Seq gene counts of unpaired 
TCGA primary tumour and normal-adjacent-tumour samples, along with 
GTEx normal samples were converted to z-scores using the scale( ) method in 
R.  The z-scores were then converted to barcodes as described above.  
 
Prior to assessment of the barcode for classification of breast tumour samples, 
the informative genes (Top DEG's) were extracted to simplify feature 
selection. 
 
For each of the classification scenarios the following filtering method was 
applied:  
1) For TCGA normal-adjacent-tumour versus TCGA tumour, the Top 100, 
75, 50 and 25 differentially expressed genes (DEG's), discovered using 
paired samples, and were extracted.  
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2) For GTEx normal versus TCGA tumour, the Top 100, Top 100, 75, 50 and 
25 differentially expressed genes (DEG's) were extracted. 
3) For the integrated GTEx-TCGA dataset (to discover a set of DEG's which 
could firstly characterize normal-adjacent-tumour samples), the overlap of 
the Top 500 and Top 1000 DEG's of each DEG analysis iteration was 
extracted from GTEx, and TCGA datasets. 
 
4.2.8 Unsupervised Machine Learning: Hierarchical and K-means 
Clustering 
Machine learning algorithms like Hierarchical clustering and K-means 
clustering are heuristic in nature and allow for initial evaluation of the strength 
and/or accuracy of a classification model.  
 
Hierarchical clustering uses agglomerative clustering – where each sample is 
initially assigned to its own cluster, two neighbouring clusters (of 1 sample 
each) are then linked to each other based on similarities. Each iteration 
continues to link similar samples to each other until distinctive clusters are 
formed – the merged clusters creating a binary tree or hierarchy.  
 
K-means clustering uses partitional clustering. The goal of the algorithm is to 
group similar samples together into k partitions (clusters). The Euclidean 
distance between samples is used to cluster similar samples together, where 
Euclidean distance inversely correlates to similarity. For each iteration of 
clustering, a sample is assigned to the closest cluster center. Each resulting 
group or partition will include samples of mutual similarity. 
 
Hierarchical clustering was first applied to the gene sets detailed in 2.4.1, and 
once the feature sets were assessed as being informative enough to accurately 
classify barcoded RNA-Seq breast tissue samples (normal, normal-adjacent-
tumour, and primary tumour),  K-means clustering was applied all datasets for 
each of the informative gene sets.  
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4.2.9 Supervised Machine Learning: Support Vector Machines 
Support Vector Machines (SVM) was employed as a supervised machine 
learning algorithm after initial evaluation of the feature sets discovered. SVMs 
allow the user to input a training set of data where class, or tissue type can be 
specified. The algorithm then calculates a “margin” or hyperplane of 
separation between samples of two different classes.  
 
Unseen validation datasets consisting of TCGA normal-adjacent-tumour and 
primary tumour, and GTEx normal samples that had been “barcoded” were 
classified using SVMs to assess if the feature sets could accurately assign 
samples to their correct known classes. The “e1071” R package was used for 
SVM classification, with the linear kernel selected for binary (two-class) and 
the radial basis function kernel selected for one-versus-one (multi-class OVO-
SVM) C-classification. 
 
The SVM classifiers (training dataset - initial datasets used in DEG analysis) 
were tested with a validation dataset of “unseen” samples for iterations as 
detailed in 2.4.1. 
 
4.3 Results 
4.3.1 Feature set discovery in a paired TCGA normal-tumour dataset 
The filtering of genes that were consistently lowly expressed lowered the number 
of genes from 60483 down to ±52 000 genes. Following DE analysis, the top 100, 
75, 50 and 25 differentially expressed genes were found to have fold changes 
greater than 2, with very low adjusted p-values (Table 4.2), suggesting that these 
feature set(s) would likely be able to definitively differentiate between normal-
adjacent-tumour and tumour samples. 
 
Prior to machine learning classification of unpaired normal-adjacent-tumour 
(NAT) and primary tumour samples was performed, hierarchical clustering was 
applied to the top 100 DEG's from each of the DEG analyses iterations; Figure 4.1 
shows 140 unpaired samples clustered with informative genes discovered using 40 
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paired samples, and Figure 4.2 shows the same 140 unpaired samples clustered 
with informative genes discovered using 80 paired samples. The DEG's extracted 
from the 80 paired sample analysis was used in subsequent, downstream analyses 
and classification, as these genes were able to distinguish between tissue types 
more accurately.  
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Table 4. 2: Top 50 DEG's extracted from differential expression analysis of 80 paired 
TCGA NAT and Primary Tumour samples. 
Differentially 
Expressed Genes 
Log Fold-Change p-Values 
FDR  
(adjusted p-
Values) 
ENSG00000249669.6 -4.434694263 1.8373E-117 9.9443E-113 
ENSG00000123500.8 7.434499304 7.8473E-113 2.1236E-108 
ENSG00000230838.1 6.210239154 1.31508E-77 2.37259E-73 
ENSG00000099953.8 6.134165335 3.41309E-77 4.39418E-73 
ENSG00000167900.10 3.161174788 4.05936E-77 4.39418E-73 
ENSG00000169241.16 2.370218283 1.2027E-75 1.08492E-71 
ENSG00000269936.3 -3.774200534 4.38549E-75 3.39086E-71 
ENSG00000137225.11 -2.864682714 1.28804E-73 8.71421E-70 
ENSG00000203805.9 5.995143604 6.09783E-71 3.6671E-67 
ENSG00000077152.8 3.345475916 1.15564E-70 6.25478E-67 
ENSG00000154736.5 -2.880787494 1.07524E-67 5.2906E-64 
ENSG00000122641.9 3.871265606 6.11414E-66 2.75768E-62 
ENSG00000119771.13 -2.675690579 7.13479E-63 2.97049E-59 
ENSG00000143549.18 1.842349082 5.66739E-61 2.19101E-57 
ENSG00000123975.4 2.538594917 1.14512E-57 4.13191E-54 
ENSG00000241684.4 -3.285083983 4.73071E-57 1.5936E-53 
ENSG00000179796.10 -4.122695034 5.00539E-57 1.5936E-53 
ENSG00000172318.5 -3.629498652 6.0258E-56 1.81189E-52 
ENSG00000148053.14 -3.526384565 8.78702E-56 2.5031E-52 
ENSG00000179094.12 -1.776648312 7.30914E-55 1.978E-51 
ENSG00000158850.13 1.648201487 1.22839E-53 3.06004E-50 
ENSG00000198932.11 -2.169099127 1.24383E-53 3.06004E-50 
ENSG00000170312.14 3.356942048 2.78003E-53 6.54201E-50 
ENSG00000083067.21 -2.926262212 3.887E-53 8.76582E-50 
ENSG00000160753.14 1.893639404 5.68973E-53 1.2318E-49 
ENSG00000117650.11 4.710060486 7.30671E-53 1.52103E-49 
ENSG00000161888.10 3.284471119 8.00579E-53 1.60483E-49 
ENSG00000090889.11 4.347664643 2.6363E-52 5.09596E-49 
ENSG00000169258.6 2.926351502 3.00573E-52 5.60973E-49 
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ENSG00000025423.10 3.256130792 6.27624E-52 1.13232E-48 
ENSG00000166803.9 3.648661362 9.33087E-52 1.58489E-48 
ENSG00000143228.11 4.067274187 9.37042E-52 1.58489E-48 
ENSG00000100526.18 3.243788354 1.04394E-51 1.71218E-48 
ENSG00000143493.11 1.56345217 1.23769E-51 1.97026E-48 
ENSG00000208035.1 -4.785676044 1.28835E-51 1.99231E-48 
ENSG00000136158.9 -2.274222562 1.49651E-51 2.24992E-48 
ENSG00000013810.17 2.436535656 2.07864E-51 3.04066E-48 
ENSG00000134690.9 3.076288541 3.65671E-51 5.20831E-48 
ENSG00000076382.15 2.646701137 8.46716E-51 1.17507E-47 
ENSG00000108924.12 -3.178286978 9.55405E-51 1.29276E-47 
ENSG00000188486.3 1.90014401 4.91226E-50 6.48467E-47 
ENSG00000065534.17 -1.953704813 5.7853E-50 7.45533E-47 
ENSG00000127564.15 4.258846765 6.82836E-50 8.59484E-47 
ENSG00000154263.16 -3.702210309 7.62125E-50 9.37484E-47 
ENSG00000079462.6 2.61127339 1.05422E-49 1.26797E-46 
ENSG00000177628.14 1.662281779 1.78839E-49 2.06772E-46 
ENSG00000168497.4 -3.659070393 1.79556E-49 2.06772E-46 
ENSG00000135094.9 3.120126981 2.35637E-49 2.657E-46 
ENSG00000149923.12 1.542231541 3.98288E-49 4.39937E-46 
ENSG00000254986.6 1.755083595 6.51367E-49 7.05092E-46 
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Figure 4. 1: Hierarchical clustering of “barcoded” TCGA Normal-Adjacent-Tumour 
(NAT) and TCGA Primary Tumour (Tumour) Unpaired RNA-Seq samples (n = 100) 
yielded 98% accuracy when classified using the Top 100 DEG's discovered using 40 
paired Normal-Adjacent-Tumour and Tumour samples. 
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Figure 4. 2: Hierarchical clustering of “barcoded” TCGA Normal-Adjacent-Tumour 
(NAT) and TCGA Primary Tumour (Tumour) Unpaired RNA-Seq samples (n = 100) 
yielded 100% accuracy when classified using the Top 100 DEG's discovered using 80 
paired Normal-Adjacent-Tumour and Tumour samples. 
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4.3.2 Feature set discovery in an integrated GTEx-TCGA dataset 
Integration of GTEx and TCGA RNA-Seq gene count data resulted in a ±6% 
and ±12% data loss due to a difference in GTEx and TCGA library sizes; 
GTEx consisting of 56203 genes and TCGA consisting of 60843 genes – 
with a resulting overlap of 53196 genes. Filtering of lowly expressed genes 
resulted in a further reduction of uninformative data, decreasing the number 
of genes to 50758.  
 
Although there was a 17% loss of TCGA primary tumour data, and 7% loss 
of GTEx normal data, the resultant top 100, 75, 50, and 25 DEG's, had very 
low adjusted p-values, and large log-fold changes (Table 4.2), suggesting 
that these DEG's could be used for feature selection prior to machine learning 
classification. 
 
4.3.3 Feature set discovery for multi-class classification of a GTEx normal, 
TCGA normal-adjacent-tumour and TCGA primary tumour 
integrated dataset 
Subsequent to discovering informative genes (DEG's) capable of discerning 
between a) TCGA normal-adjacent-tumour and primary tumour samples, and 
b) GTEx normal (healthy) and TCGA primary tumour samples, the overlap 
of these two DEG analyses experimental designs yielded only 1 gene in 
common when comparing the top 100 DEG's.  
 
Intersecting the top 500 and top 1000 statistically significant DEGs of each 
analysis yielded 59 and 216 genes, respectively.  
 
These sets were used as features for multi-class classification modelling to 
determine the presence of a distinct gene expression signature for normal-
adjacent-tumour samples from cancer patients when compared to normal 
breast from healthy women. 
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4.3.4 Z-scores and “Barcoding” RNA-Seq gene counts 
The heatmap in Figure 4.3 indicates that the top 100 DEG's discovered with 
edgeR accurately separate normal samples from tumour samples. The z-
scores generated to produce the map allow the differences in relative gene 
expression levels between the two tissue types to be easily visualized. The 
TCGA normal-adjacent-tumour samples appear on the left-side of the 
heatmap, with TCGA primary tumour samples appearing on the right-side of 
the image. This indicated that these z-scores could be converted to 1's and 0's 
to generate a barcode for normal and tumour samples. In order to mimic the 
Gene Expression Barcode's (GExB) single sample algorithm (barcoding of a 
single microarray sample) (McCall et al., 2014, 2011), which would produce 
statistically derived absolute gene expression calls, the R scale()function was 
applied to each sample independently of other samples from the same tissue 
type, i.e. normal-adjacent-tumour or primary tumour, unlike typical 
application of z-score to cancer genomic data which scales the raw gene 
count data across the tissue (Colaprico, Olsen, supervisor, & Bontempi 
Biopark Charleroi, 2016).  Scaling of data with similar statistical methods, 
has been shown to improve classification of TCGA data (Rahman et al., 
2015). We hypothesized that z-scores and their conversion to 
absence/presence calls would perform similarly, as they were previously 
applied in RNA-Seq data to infer gene expression (Siegfried et al., 2015). 
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Figure 4. 3: Z-Score Heatmap of Paired Normal-Tumour Samples using Top 100 DEGs 
as a feature set 
 
4.3.5 Machine Learning classification 
4.3.5.1 Clustering and SVM classification of TCGA data 
K-means clustering was able to use the expression barcode generated from 
DEG's discovered on paired TCGA samples to classify 140 unpaired TCGA 
normal-adjacent-tumour and primary tumour samples with above 95% 
accuracy.  Hierarchical clustering and SVM binary classification improved 
the accuracy to 100% (Table 4.3). 
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Table 4. 3: Classification results of TCGA Normal-Adjacent-Tumour (NAT) and TCGA 
Primary Tumour (Tumour) Unpaired RNA-Seq samples (n = 140) 
 K-means 
Hierarchical 
Clustering 
SVM 
 NAT Tumour NAT Tumour NAT Tumour 
Top100 DEG 100% 98% 100% 100% 100% 100% 
Top75 DEG 99% 98% 100% 100% 100% 100% 
Top50 DEG 100% 97% 100% 100% 100% 100% 
Top25 DEG 100% 98% 100% 100% 100% 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.5.2 Clustering and SVM classification of GTEx-TCGA integrated data 
K-means clustering, hierarchical clustering and SVM were all able to use the 
barcode discovered using the dataset of 200 samples to classify 100 unseen GTEx 
normal and TCGA primary samples with 100% accuracy (Table 4.4). 
 
Table 4. 4: Classification results of GTEx Normal (Normal) and TCGA Primary Tumour 
(Tumour) Test RNA-Seq samples (n = 100) 
K-means 
Hierarchical 
Clustering 
SVM 
 Normal Tumour Normal Tumour Normal Tumour 
Top100 DEG 100% 100% 100% 100% 100% 100% 
Top75 DEG 100% 100% 100% 100% 100% 100% 
Top50 DEG 100% 100% 100% 100% 100% 100% 
Top25 DEG 100% 100% 100% 100% 100% 100% 
 
4.3.5.3 Multi-class classification of healthy breast, normal-adjacent-tumour 
(NAT) and primary tumour tissues 
Clustering analysis using the barcodes generated for the 59 gene and 216 gene 
signatures described in 3.1.3 on 300 samples of GTEx normal, TCGA NAT, and 
TCGA primary tumour revealed that both were discriminatory features to 
accurately separate the three tissue types (Figures 4.4 and 4.5). NAT tissue was 
also shown to be a “subtype” of normal samples, distinct from breast tissue from 
the healthy individuals in GTEx.  
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Figure 4. 4: Barcode-based hierarchical clustering of 300 GTEx and TCGA samples, 
yielded 98% accuracy when classified with the Top 59-overlapping DEG’s (described in 
Sections 4.2.5 and 4.3.3). 
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Figure 4. 5: Barcode-based hierarchical clustering of 300 GTEx and TCGA samples, 
yielded 100% accuracy when classified with the Top 216-overlapping DEG’s (described 
in Sections 4.2.5 and 4.3.3). 
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Validation of these gene sets to correctly characterize a sample as normal 
(healthy), normal-adjacent-tumour (from a cancer patient), or primary breast 
tumour (cancer) was performed with a test dataset of unseen samples. K-means 
and hierarchical clustering results (Table 4.5) showed that unsupervised machine 
learning methods could classify samples with above 85% accuracy.   
 
Table 4. 5: Classification results of GTEx Normal (Normal), TCGA Normal-Adjacent-
Tumour (NAT) and TCGA Primary Tumour (Tumour) RNA-Seq samples with Validation 
dataset 
 K-means 
Hierarchical 
Clustering 
 
GTEx 
Normal 
TCGA 
NAT 
TCGA 
Tumour 
GTEx 
Normal 
TCGA 
NAT 
TCGA 
Tumour 
59 DEG 100% 92% 90% 100% 92% 100% 
216 DEG 100% 85% 86% 100% 92% 100% 
 
A multi-class one-versus-one support vector machine (multi-class OVO-SVM) 
trained on the 300 samples hierarchically clustered in figures 4.4 and 4.5 above, 
and tested with 113 unseen samples (classified with K-means and hierarchical 
clustering in table 4.4 above) was able to distinguish between the three different 
tissue types with above 99% accuracy (Table 4.6). 
 
Table 4. 6: Overlap of Top DEG’s: SVM classification with Validation dataset 
Tissue Type No. samples tested Classification accuracy 
  59 DEG's 216 DEG's 
GTEx Normal 50 98% (49) 100% (50) 
TCGA Normal-
Adjacent-Tumour 
13 100% (13) 100% (13) 
TCGA Primary 
Tumour 
50 100% (50) 100% (50) 
    
Total: 113 99.12% 100% 
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Figure 4. 6: Heatmap of 59 DEG's separating GTEx normal, TCGA NAT, and TCGA 
tumour tissues 
4.4 Discussion 
RNA-Seq DE analysis and sample-level Z-Score data transformation 
produced phenotypically accurate segregating expression portraits  
The edgeR package, when applied to TCGA paired normal-adjacent-tumour and 
tumour samples, as well as GTEx-TCGA integrated data reported robust sets of 
differentially expressed genes (DEG's), as evidenced by their very high log-fold 
changes and small adjusted p-values. Our application of the R scale() function to 
each sample independently of other samples from the same tissue type revealed a 
“transcriptomic portrait” of genes switched on and off in that sample, which could 
be integrated with other samples  of the same type for feature selection. 
 
The suitability of our strategy is illustrated by a heatmap of scaled data, i.e. z-
http://etd.uwc.ac.za/
90 
 
scores, in Figure 4.3, which shows mostly uniform within-class up or down 
regulation of extracted DEG's signatures across the tissue types.  
 
RNA-Seq Barcodes of DEG’s produces powerful classification signatures 
The conversion of these z-scores to a “barcode”, 1's and 0’s proved robust for 
classification of TCGA data. Figure 4.2 and Table 4.2 demonstrated that using 
multi-tissue RNA-Seq barcodes of pre-identified DEG's as classification features 
was remarkably accurate in identifying a samples as malignant (primary tumour) 
or normal. 
 
The degree of classification accuracy (Table 4.6) attained when applying the 
approach to the integrated RNA-Seq data from GTEx (breast tissue from healthy 
women) and TCGA (tumour and adjacent normal) was still more notable, given 
that multi-class classification is inherently more difficult and the fact that data was 
lost during integration. Thus our approach of DEG discovery coupled with z-
score-to-barcode data transformation, proved to be a reliable way of identifying 
robust predictive gene signatures in integrated data from multiple sources. 
 
In recent years, the emergence of in-depth transcriptome profiling has led to a few 
diagnostic and prognostic gene expression signatures being developed from RNA-
Seq data. Most notably, a lung adenocarcinoma 4-gene prognostic signature 
(Shukla et al., 2017), and a colorectal cancer 12-gene prognostic signature (Sun et 
al., 2018), developed with TCGA RNA-Seq data and survival analysis algorithms. 
Studies which were aimed at building classifiers for subtyping and staging of 
cancers, with SVM implementation however, are more closely comparable to this 
study. A cancer diagnostic classifier based on gene expression (RNA-Seq data) of 
blood platelets was able to classify cancer subtypes with above 75% accuracy 
with SVM implementation (Y.-H. Zhang et al., 2017). A breast cancer staging 
classifier which could determine early or late stage cancer, implemented SVM  
recursive feature elimination (SVM-RFE) and was able to classify with tumours 
with above 98% accuracy (Yao, Zhang, Du, Liu, & Xu, 2015). In contrast, the 
two-class (normal versus tumour) and the multi-class classifiers developed were 
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able to classify unseen samples with 100% accuracy.  
 
We thus propose that our method of sample-level z-score based barcoding of 
RNA-Seq data is analogous to the Gene Expression Barcode algorithm designed 
specifically for microarray data and has likely future utility in discovery of 
predictive signatures in other study scenarios. As several of the signature genes 
were previously described as novel RNA-Seq derived biomarkers (Wang, 
Gerstein, & Snyder, 2009), we further propose that the signatures may have 
potential for breast cancer diagnostics R&D, since the absence-presence calls can 
be readily and simply assessed using qtPCR.  
 
NAT tissues classify separately from healthy and tumour tissues 
When overlapping the top 500 and top 1000 DEG's from TCGA and GTEx-
TCGA analysis, barcode signatures of 59 and 216 genes emerged which were able 
to distinguish between the three different tissue types, respectively. NAT tissue 
presents with a distinctly different transcriptome portrait when compared to 
normal samples acquired from healthy individuals (GTEx) and primary breast 
tumours from TCGA, as represented in Figure 4.6.  
 
These observations are strongly supported by previous studies geared towards the 
elucidation of the molecular profiles of histologically normal tissues adjacent to 
malignant breast tumours. A study undertaken by Boston University School of 
Medicine revealed that 25-53% of the genes over-expressed or under-expressed in 
estrogen-receptor positive or negative breast tumours were shared with normal-
adjacent-tumour tissue samples (Kelly Graham, Ge, de Las Morenas, Tripathi, & 
Rosenberg, 2011). These findings were echoed in a 2015 study which revealed 
that intrinsic tumour subtypes (PAM50 subtypes) were reflected in histologically 
normal-adjacent-tumour tissues, and suggested that the shared molecular 
portrait(s) may account for cancer recurrence and the derivation of biomarkers 
may be plausible (Casbas-Hernandez et al., 2015).  
Aran and colleagues took the above into account and investigated the NAT 
transcriptome.  Their analysis spanned a few different cancers and included the 
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integration of normal tissues from healthy individuals (GTEx project). It was 
revealed that not only did NAT tissue share a partial molecular profile with 
tumour samples, and a partial molecular profile with healthy tissues, but also 
possessed its own gene expression signatures (Aran et al., 2017). Furthermore, 
they hypothesize that the distinct molecular portrait of NAT tissues may in fact be 
attributed to the tumour's effect on the adjacent tumours due to particular genes 
being up-regulated in NAT tissues which are linked to molecular subtypes, and 
immune response pathways. Upon closer examination of Figure 4.5, within the 
216 informative gene set, NAT tissues appear as a “subtype” of normal in relation 
to GTEx normal, but are more closely related to tumour samples. This is and can 
be deduced from Figure 4.6, where some genes of NAT tissues begin to exhibit.    
 
The experimental design of cancer studies aimed at gene signature discovery thus 
needs to takes these findings into account. More expansive research is required 
with larger sample numbers, to discover a “universal” signature which can 
definitively distinguish between normal and normal-adjacent-tumour samples. 
Although Table 4.3 reveals a possible robust gene signature to classify tumour 
samples accurately, there was no overlap between the Top 100 DEG's from 
TCGA normal versus tumours and the Top 100 DEG's from GTEx normal versus 
TCGA tumour. Researchers may be missing possible biomarkers/gene signatures 
which are more discriminative in cancer classification due to the overlap of genes 
expressed between NAT and tumour tissues (Figure and Table 4.6). In order to 
build true multi-class classifiers which can distinguish between normal, normal-
adjacent-tumour (pre-cancer), and different molecular or intrinsic subtypes of 
breast cancer, NAT tissues must be treated as separate class from healthy-normal 
samples, and an integration of the two in biomarker discovery may prove 
beneficial in robust and accurate cancer classifier development.   
 
Limitations to integrative RNA-Seq data analysis 
Comprehensive studies which can reveal novel insights into tumorigenesis, 
metastases, and progression of cancers, including breast cancer, is limited by not 
only the amount of data available for normal-adjacent-tumour tissues and normal 
http://etd.uwc.ac.za/
93 
 
(healthy) samples but also by the steps necessary to integrate such data.  
 
The integration of data from The GTEx and TCGA projects resulted in the loss of 
potentially informative genes due to differences in study designs, and gene 
definitions used. Although publicly available data from NCBI GEO may aid in 
increasing dataset size for DEG discovery and serve as validation sets, this too 
possesses constraints due to difference in sequencing platforms – Illumina HiSeq 
2000 for GTEx and TCGA data, Illumina HiSeq 2500, 3000 & 4000 for the 
majority of transcriptomic data published in NCBI GEO. A possible solution to 
integrating RNA-Seq data generated on different platforms may also require 
accessing raw data, post assembly and alignment of transcripts, and generating 
HTSeq counts prior to differential expression analysis may better normalize the 
expression counts used.   
4.5 Conclusions 
The integration of GTEx and TCGA data allowed for the discovery of a very 
distinct NAT tissue gene expression profile. Each iteration of differential 
expression analysis revealed three different classifiers that all classified unseen 
data with 100% accuracy. Although a distinctly different molecular portrait of 
TCGA NAT tissues was revealed, the 10,000 genes not present in the GTEx gene 
library, contributed to a set of informative genes still capable of segregating 
tumour samples from normal samples. Thus NAT tissues may still serve as a 
control in cancer transcriptomic studies, along with the additional advantages of 
easy biospecimen accessibility during tumour biopsy collection.  
 
The development of a barcoding method for RNA-Seq gene count data proved 
robust in transforming continuous data and enabled an “ease” of tissue 
discrimination to classifier development. The results obtained, albeit convincingly 
validated on an unseen dataset, could be further assessed with samples from other 
study consortia. Further investigation of NAT differentiating genes through 
function and pathway enrichment analysis may also ascertain their molecular roles 
in tumorigenesis and potential as both early breast cancer detection biomarkers 
and candidate drug targets. 
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CHAPTER 5 
Conclusions and Future Work 
 
The primary aim of our study was to integrate breast cancer microarray expression 
data using the GExB algorithm to discover easily assayable signatures for breast 
cancer subtypes. We also aimed to extend this to RNA-Seq data, with the 
implementation of our own RNA-Seq barcode method.   
 
5.1 Conclusion 
Transformation of expression data into barcodes simplifies discovery of 
features that are able to discriminate between sample types. Used in 
combination with machine learning and customised feature selection, gene 
expression barcodes produced signatures that clearly separate breast cancer 
subtypes.  
 
Enrichment analysis of both the microarray and RNA-Seq gene signatures 
revealed that unbiased approaches to FS can greatly enhance the biologically 
relevant discoveries made in bioinformatics. Within both gene signatures, 306 
known genes from microarray and 213 known genes from RNA-Seq, diseases 
in which these genes were involved included cancers of the skin (melanoma), 
lung, liver, kidneys, breast, endometrium (uterine), leukaemia, as well as 
illnesses with a known inflammatory nature such as arthritis, lupus 
erythematosus, and Crohn's disease. Moreover, the both sets were found to be 
statistically enriched for biological pathways and processes relevant to cancer, 
including: apoptosis, p53 signalling, and signalling pathways regulating 
pluripotency of stem cells. 
 
The barcoding method developed for RNA-Seq data holds promise for 
implementation in biomarker discovery for cancer in the NGS era. The NAT 
specific profile discovered was easily detectable and visualized with data 
transformation from continuous data to discrete data. Interrogation of the 
informative gene sets, in particular GTEx normal versus TCGA primary 
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tumour, 36 novel genes were involved in an accurate classifier being 
developed. These results pose various questions to cancer researchers 
surrounding not only differential expression analysis of tumours' experimental 
design, but also the very nature of normal tissues surrounding tumours and the 
possible biological insights into cancer metastases (Pietras & Östman, 2010). 
Mechanisms of tumorigenesis and the tumour's interaction with its 
surrounding environment needs to be closely investigated to fully elucidate the 
unique portrait of NAT tissues (Grivennikov, Greten, & Karin, 2010; Terzić, 
Grivennikov, Karin, & Karin, 2010).  
 
Haibe-Kains speculated in an article about classification models for breast 
cancer using gene expression could, “if widely used in a standardized fashion, 
could dramatically change the way in which patients are managed in a clinical 
setting and, hopefully, could lead to substantial improvements in outcome and 
survival” (Haibe-Kains, 2010). The potential to design and implement clinical 
assays, e.g. qtPCR, from RNA-Seq discovered biomarkers is clearly illustrated 
through the methods developed, implemented and validated throughout this 
research study. 
 
5.2 Discovered signatures are applicable across technologies  
As a final step in validating both the gene expression signatures discovered on 
microarray data, as well as the RNA-Seq z-score-to-barcode method, 
classification of RNA-Seq barcoded samples was performed with the two-
class microarray feature set. The 85 microarray probes were mapped to 
Ensembl gene ID's used in Illumina HiSeq 2000 sequencing data. This 
resulted in 75 genes, which were then extracted from 300 barcoded RNA-Seq 
breast tissue samples – 100 GTEx normal, 100 TCGA NAT and 100 TCGA 
Tumour. Hierarchical clustering resulted in 95.33% accurate classification of 
barcoded RNA-Seq samples.  
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5.3 Future Work 
To discover a more informative and probe/gene set for multiclass breast 
cancer classification, data slicing should be considered. This would entail 
analysing the classes of breast cancer in a one-versus-one (OVO) rather than 
OVR fashion to identify genes or probes that distinguish one subtype from 
another. Intersecting the OVO-FS discovered probes could allow a smaller but 
more informative probe set to be determined.  
 
Data curation, however extensive, was limited and could be extended to a far 
larger dataset. The poorly labelled samples and mislabelled samples could be 
considered as ambiguous and be further explored using the original 346-gene 
signature, then using those assigned classes to build a larger training dataset. 
While further evaluation of the RNA-Seq barcoding technique is necessary, 
our results point to its potential for application to other cancers, as well as 
other diseases or R&D applications that could benefit from accurate 
classification of clinical phenotypes, therapeutic responses and expected 
survival times, etc. 
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7 Appendices 
Appendix I 
Table 7. 1: Microarray breast tissue samples curated 
Tissue Type GEO* Series GEO Accession 
Numbers 
GEO Platform 
(Affymetrix™) 
Normal Epithelium GSE20437 GSM512539 
GSM512540 
GSM512541 
GSM512542 
GSM512543 
GSM512544 
GSM512545 
GSM512546 
GSM512547 
GSM512548 
GSM512549 
GSM512550 
GSM512551 
GSM512552 
GSM512553 
GSM512554 
GSM512555 
GSM512556 
 
GPL96** 
GSE9574 GSM241999 
GSM242000 
GSM242001 
GSM242002 
GSM242003 
GSM242004 
GSM242005 
GSM242006 
GSM242007 
GSM242008 
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GSM242009 
GSM242010 
GSM242011 
GSM242012 
GSM242013 
GSM242014 
GSM242015 
GSM242016 
GSM242017 
GSM242018 
 
Normal Duct GSE5764 GSM134584 
GSM134588 
GSM134687 
GSM134690 
GSM134693 
GSM134696 
GSM134699 
GSM134702 
GSM134705 
GSM134708 
 
GPL570*** 
Normal Lobe GSE5764 GSM134586 
GSM134589 
GSM134688 
GSM134691 
GSM134694 
GSM134697 
GSM134700 
GSM134703 
GSM134706 
GSM134709 
 
GPL570 
Triple Negative Breast 
Tumour 
GSE25065 GSM615637 
GSM615639 
GSM615640 
GSM615644 
GPL96 
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GSM615650 
GSM615651 
GSM615657 
GSM615658 
GSM615660 
GSM615661 
GSM615666 
GSM615667 
GSM615668 
GSM615671 
GSM615672 
GSM615674 
GSM615677 
GSM615680 
GSM615681 
GSM615687 
GSM615689 
GSM615691 
GSM615694 
GSM615696 
GSM615699 
GSM615707 
GSM615712 
GSM615714 
GSM615715 
GSM615716 
GSM615727 
GSM615733 
GSM615739 
GSM615742 
GSM615744 
GSM615746 
GSM615757 
GSM615762 
GSM615764 
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GSM615766 
GSM615769 
GSM615773 
GSM615776 
GSM615780 
GSM615784 
GSM615785 
GSM615823 
GSM615824 
GSM615827 
 
GSE31519 GSM782523 
GSM782524 
GSM782525 
GSM782526 
GSM782527 
GSM782528 
GSM782529 
GSM782530 
GSM782531 
GSM782532 
GSM782533 
GSM782534 
GSM782535 
GSM782536 
GSM782537 
GSM782538 
GSM782539 
GSM782540 
GSM782541 
GSM782542 
GSM782543 
 
Estrogen-Positive 
Breast Tumour 
GSE25065 GSM615638 
GSM615648 
GSM615656 
GPL96 
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GSM615669 
GSM615688 
GSM615701 
GSM615702 
GSM615703 
GSM615708 
GSM615709 
GSM615718 
GSM615725 
GSM615728 
GSM615730 
GSM615732 
GSM615736 
GSM615737 
GSM615741 
GSM615748 
GSM615754 
GSM615761 
GSM615767 
GSM615774 
GSM615782 
GSM615783 
GSM615796 
GSM615809 
GSM615819 
GSM615822 
 
GSE23988 GSM590841 
GSM590843 
GSM590844 
GSM590845 
GSM590846 
GSM590847 
GSM590849 
GSM590854 
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GSM590856 
GSM590857 
GSM590859 
GSM590861 
 
 GSE22093 GSM549241 
GSM549247 
GSM549258 
GSM549259 
GSM549261 
GSM549264 
GSM549266 
GSM549269 
GSM549270 
GSM549272 
 
 
Her2-Positive Breast 
Tumour 
GSE42822 GSM105051 
GSM105051 
GSM105060 
GSM105068 
GSM105068 
GSM105062 
GSM105064 
GSM105065 
GSM105068 
GSM105062 
GSM105065 
GSM105067 
GSM105069 
GSM105060 
GSM105063 
GSM105064 
GSM105065 
GSM105067 
 
GPL96 
GSE37946 GSM930525 
GSM930526 
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GSM930527 
GSM930528 
GSM930530 
GSM930531 
GSM930533 
GSM930534 
GSM930535 
GSM930539 
GSM930541 
GSM930542 
GSM930543 
GSM930544 
GSM930546 
GSM930547 
GSM930549 
GSM930551 
GSM930552 
GSM930555 
GSM930557 
GSM930558 
GSM930559 
GSM930560 
GSM930561 
GSM930563 
GSM930564 
GSM930566 
GSM930568 
GSM930569 
GSM930571 
GSM930574 
 
Primary Breast 
Tumour 
GSE21217 GSM530556 
GSM530557 
GSM530558 
GSM530559 
GPL96 
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GSM530560 
GSM530561 
GSM530562 
GSM530563 
GSM530564 
GSM530565 
GSM530566 
 
GSE5462 GSM125123 
GSM125125 
GSM125127 
GSM125129 
GSM125131 
GSM125133 
GSM125135 
GSM125137 
GSM125139 
GSM125141 
 
Inflammatory Breast 
Tumour 
GSE5847 GSM136373 
GSM136374 
GSM136375 
GSM136376 
GSM136377 
GSM136378 
GSM136379 
GSM136380 
GSM136381 
GSM136382 
GSM136383 
GSM136384 
GSM136385 
 
GPL570 
GSE22597 GSM560663 
GSM560664 
GSM560665 
GSM560666 
GPL96 
http://etd.uwc.ac.za/
125 
 
GSM560667 
GSM560668 
GSM560669 
GSM560670 
GSM560671 
GSM560672 
GSM560673 
GSM560674 
GSM560675 
GSM560676 
GSM560677 
GSM560678 
GSM560679 
GSM560680 
GSM560681 
GSM560682 
GSM560683 
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Appendix II 
GTEx Data Curated 
Table 7. 2: Normal breast tissue samples filtered from GTEx Version 7 Gene Counts file 
Training Data – GTEx Sample ID Sample Name 
GTEX-1117F-2826-SM-5GZXL GTEx-Norm1 
GTEX-111YS-1926-SM-5GICC GTEx-Norm2 
GTEX-1122O-1226-SM-5H113 GTEx-Norm3 
GTEX-117XS-1926-SM-5GICO GTEx-Norm4 
GTEX-117YX-1426-SM-5H12H GTEx-Norm5 
GTEX-1192X-2326-SM-5987X GTEx-Norm6 
GTEX-11DXW-0626-SM-5N9ER GTEx-Norm7 
GTEX-11DXY-2326-SM-5GICW GTEx-Norm8 
GTEX-11DXZ-1926-SM-5GZZL GTEx-Norm9 
GTEX-11DZ1-0326-SM-5N9BN GTEx-Norm10 
GTEX-11EI6-0626-SM-5985T GTEx-Norm11 
GTEX-11EM3-1326-SM-5N9C6 GTEx-Norm12 
GTEX-11EMC-2026-SM-5A5JV GTEx-Norm13 
GTEX-11EQ9-1826-SM-5Q5AJ GTEx-Norm14 
GTEX-11GS4-2126-SM-5A5KR GTEx-Norm15 
GTEX-11GSO-1926-SM-5A5K3 GTEx-Norm16 
GTEX-11I78-2226-SM-5PNYA GTEx-Norm17 
GTEX-11LCK-2426-SM-5HL5F GTEx-Norm18 
GTEX-11NSD-0926-SM-5N9DR GTEx-Norm19 
GTEX-11NV4-2026-SM-5N9DG GTEx-Norm20 
GTEX-11O72-2126-SM-5N9FO GTEx-Norm21 
GTEX-11OF3-1926-SM-59889 GTEx-Norm22 
GTEX-11ONC-2126-SM-5HL6E GTEx-Norm23 
GTEX-11P7K-0726-SM-5EGKX GTEx-Norm24 
GTEX-11P81-1926-SM-5BC53 GTEx-Norm25 
GTEX-11P82-1326-SM-5HL62 GTEx-Norm26 
GTEX-11PRG-0826-SM-5EQ6A GTEx-Norm27 
GTEX-11TT1-2126-SM-5GU5Y GTEx-Norm28 
GTEX-11TUW-1826-SM-5BC5D GTEx-Norm29 
GTEX-11WQC-1726-SM-5GU4W GTEx-Norm30 
GTEX-11WQK-2426-SM-5GU5C GTEx-Norm31 
GTEX-11ZTT-2326-SM-5EQLG GTEx-Norm32 
GTEX-11ZUS-0826-SM-5FQUY GTEx-Norm33 
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GTEX-1211K-1926-SM-5EQLB GTEx-Norm34 
GTEX-1269C-2426-SM-5FQSN GTEx-Norm35 
GTEX-12BJ1-1826-SM-5HL9N GTEx-Norm36 
GTEX-12KS4-0126-SM-5Q5A5 GTEx-Norm37 
GTEX-12WSK-2226-SM-5GCO5 GTEx-Norm38 
GTEX-12WSM-1726-SM-5BC6J GTEx-Norm39 
GTEX-12WSN-1326-SM-5GCNT GTEx-Norm40 
GTEX-12ZZX-1126-SM-5EGKB GTEx-Norm41 
GTEX-13113-1726-SM-5GCOO GTEx-Norm42 
GTEX-1313W-0826-SM-5EQ4T GTEx-Norm43 
GTEX-1314G-1226-SM-5BC6D GTEx-Norm44 
GTEX-131XW-0726-SM-5EGK3 GTEx-Norm45 
GTEX-131YS-0626-SM-5EGKL GTEx-Norm46 
GTEX-132AR-0826-SM-5EGK6 GTEx-Norm47 
GTEX-132NY-0826-SM-5K7Y7 GTEx-Norm48 
GTEX-133LE-1726-SM-5K7VQ GTEx-Norm49 
GTEX-1399U-1826-SM-5PNZ1 GTEx-Norm50 
GTEX-139T6-1626-SM-5PNYZ GTEx-Norm51 
GTEX-139T8-0826-SM-5L3DE GTEx-Norm52 
GTEX-139TU-0626-SM-5KM3X GTEx-Norm53 
GTEX-13CF2-2026-SM-5K7VI GTEx-Norm54 
GTEX-13CF3-2126-SM-5IFJP GTEx-Norm55 
GTEX-13D11-1026-SM-5IJFB GTEx-Norm56 
GTEX-13FHO-0826-SM-5L3E8 GTEx-Norm57 
GTEX-13FTW-1426-SM-5LZWZ GTEx-Norm58 
GTEX-13FTX-1126-SM-5N9EN GTEx-Norm59 
GTEX-13FTY-2226-SM-5J1ND GTEx-Norm60 
GTEX-13N11-1726-SM-5J1OJ GTEx-Norm61 
GTEX-13N1W-0626-SM-5MR4U GTEx-Norm62 
GTEX-13NZ8-0126-SM-5IJCT GTEx-Norm63 
GTEX-13NZ9-1026-SM-5MR5K GTEx-Norm64 
GTEX-13NZB-2126-SM-5MR4Y GTEx-Norm65 
GTEX-13O3O-0826-SM-5K7WE GTEx-Norm66 
GTEX-13O3P-0826-SM-5L3DH GTEx-Norm67 
GTEX-13O3Q-2226-SM-5KM4O GTEx-Norm68 
GTEX-13O61-1826-SM-5KM4I GTEx-Norm69 
GTEX-13OW5-2226-SM-5L3HC GTEx-Norm70 
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GTEX-13OW8-0226-SM-5K7UP GTEx-Norm71 
GTEX-13PL6-2926-SM-5L3I2 GTEx-Norm72 
GTEX-13PVQ-1026-SM-5KM3M GTEx-Norm73 
GTEX-13PVR-2226-SM-7DHKP GTEx-Norm74 
GTEX-13QIC-2326-SM-5LU5N GTEx-Norm75 
GTEX-13QJ3-0826-SM-7DHKK GTEx-Norm76 
GTEX-13SLW-2526-SM-62LDQ GTEx-Norm77 
GTEX-13SLX-2326-SM-5ZZWE GTEx-Norm78 
GTEX-13VXU-2826-SM-664MA GTEx-Norm79 
GTEX-13W3W-1226-SM-5LU4H GTEx-Norm80 
GTEX-13W46-0826-SM-5LU3H GTEx-Norm81 
GTEX-144GL-2026-SM-5LU3O GTEx-Norm82 
GTEX-144GM-0926-SM-5O994 GTEx-Norm83 
GTEX-145LT-0726-SM-5S2VM GTEx-Norm84 
GTEX-145ME-1526-SM-5Q5F2 GTEx-Norm85 
GTEX-145MF-2226-SM-7EPIR GTEx-Norm86 
GTEX-145MN-1926-SM-5SIAI GTEx-Norm87 
GTEX-145MO-0826-SM-5NQBL GTEx-Norm88 
GTEX-146FH-0826-SM-5SI8T GTEx-Norm89 
GTEX-14753-2426-SM-5LU8U GTEx-Norm90 
GTEX-147F4-2826-SM-5NQBN GTEx-Norm91 
GTEX-14A5I-0726-SM-5TDEB GTEx-Norm92 
GTEX-14AS3-1626-SM-5S2OY GTEx-Norm93 
GTEX-14B4R-1226-SM-5TDDT GTEx-Norm94 
GTEX-14BMU-1626-SM-5TDE7 GTEx-Norm95 
GTEX-14BMV-0626-SM-793AU GTEx-Norm96 
GTEX-14DAR-1326-SM-7DUEG GTEx-Norm97 
GTEX-14E6C-1326-SM-62LEQ GTEx-Norm98 
GTEX-14E6E-1326-SM-5S2NR GTEx-Norm99 
GTEX-14E7W-0826-SM-62LEJ GTEx-Norm100 
  
Test Data – GTEx Sample ID Sample Name 
GTEX-14H4A-2526-SM-5YYAY GTEx-Norm101 
GTEX-14ICK-2426-SM-6EU27 GTEx-Norm102 
GTEX-14LLW-0626-SM-62LFC GTEx-Norm103 
GTEX-14PHY-1926-SM-5YY95 GTEx-Norm104 
GTEX-14PJ4-2126-SM-6ETZJ GTEx-Norm105 
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GTEX-14PJO-0726-SM-69LO8 GTEx-Norm106 
GTEX-14PKU-0426-SM-6EU1P GTEx-Norm107 
GTEX-14PN4-0626-SM-62LFP GTEx-Norm108 
GTEX-15DCZ-0726-SM-69LOV GTEx-Norm109 
GTEX-15EOM-5019-SM-793DK GTEx-Norm110 
GTEX-15ER7-1626-SM-6PAMZ GTEx-Norm111 
GTEX-15ETS-0626-SM-7KUMX GTEx-Norm112 
GTEX-15FZZ-0726-SM-7KUFZ GTEx-Norm113 
GTEX-15G19-2126-SM-6M48J GTEx-Norm114 
GTEX-15RJE-2626-SM-7KFT1 GTEx-Norm115 
GTEX-15SHW-1326-SM-6PAL8 GTEx-Norm116 
GTEX-15UF6-0126-SM-6PAMB GTEx-Norm117 
GTEX-15UF7-0726-SM-6M46D GTEx-Norm118 
GTEX-16BQI-1026-SM-7KUEA GTEx-Norm119 
GTEX-16NGA-0826-SM-718AF GTEx-Norm120 
GTEX-16YQH-2826-SM-6PAMY GTEx-Norm121 
GTEX-17EUY-1926-SM-7DUF6 GTEx-Norm122 
GTEX-17EVP-0226-SM-79OND GTEx-Norm123 
GTEX-17EVQ-0426-SM-7LG57 GTEx-Norm124 
GTEX-17F96-2426-SM-7IGLN GTEx-Norm125 
GTEX-17F97-2526-SM-7EWDV GTEx-Norm126 
GTEX-17F98-0526-SM-79OK5 GTEx-Norm127 
GTEX-17GQL-0326-SM-7LG5U GTEx-Norm128 
GTEX-17HG3-0126-SM-7IGNH GTEx-Norm129 
GTEX-17HGU-1326-SM-79OKB GTEx-Norm130 
GTEX-17HHE-1426-SM-7EPH4 GTEx-Norm131 
GTEX-17HHY-0926-SM-793C1 GTEx-Norm132 
GTEX-17JCI-0726-SM-7EPH1 GTEx-Norm133 
GTEX-17KNJ-2026-SM-7LG53 GTEx-Norm134 
GTEX-17MF6-0326-SM-7EPH5 GTEx-Norm135 
GTEX-17MFQ-0926-SM-7LG4S GTEx-Norm136 
GTEX-183FY-1126-SM-7DHLJ GTEx-Norm137 
GTEX-183WM-0726-SM-7LTAA GTEx-Norm138 
GTEX-18465-2026-SM-718AP GTEx-Norm139 
GTEX-18A6Q-0926-SM-7LG4N GTEx-Norm140 
GTEX-18A7A-0726-SM-7LTAI GTEx-Norm141 
GTEX-18A7B-2626-SM-7LG55 GTEx-Norm142 
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GTEX-18D9A-1526-SM-7LG4J GTEx-Norm143 
GTEX-18QFQ-0826-SM-718AX GTEx-Norm144 
GTEX-1A3MV-1626-SM-731C1 GTEx-Norm145 
GTEX-1A3MX-2726-SM-718B6 GTEx-Norm146 
GTEX-1A8G7-2426-SM-731AK GTEx-Norm147 
GTEX-1AMEY-1026-SM-718AA GTEx-Norm148 
GTEX-1AX8Z-0926-SM-731AW GTEx-Norm149 
GTEX-1AX9I-0726-SM-73KWV GTEx-Norm150 
GTEX-1AX9J-1126-SM-731B7 GTEx-Norm151 
GTEX-1B8KE-1226-SM-73KWK GTEx-Norm152 
GTEX-1B8KZ-1526-SM-7DUG7 GTEx-Norm153 
GTEX-1B932-0826-SM-73KXG GTEx-Norm154 
GTEX-1B933-2526-SM-7IGO5 GTEx-Norm155 
GTEX-1B97I-0426-SM-79OL7 GTEx-Norm156 
GTEX-1B97J-0426-SM-79OLQ GTEx-Norm157 
GTEX-1BAJH-0826-SM-7EWEF GTEx-Norm158 
GTEX-1C64O-0726-SM-7DUFU GTEx-Norm159 
GTEX-1C6VQ-0426-SM-79OOX GTEx-Norm160 
GTEX-1C6VS-0726-SM-7EPHF GTEx-Norm161 
GTEX-1CAMR-1426-SM-793BO GTEx-Norm162 
GTEX-1CAMS-1426-SM-7IGPM GTEx-Norm163 
GTEX-1CB4E-0226-SM-79OLW GTEx-Norm164 
GTEX-1CB4G-2326-SM-79OOI GTEx-Norm165 
GTEX-1CB4J-1826-SM-7EWF9 GTEx-Norm166 
GTEX-1E2YA-2726-SM-7IGPW GTEx-Norm167 
GTEX-1EKGG-2626-SM-7IGPY GTEx-Norm168 
GTEX-1EU9M-2826-SM-7EWFH GTEx-Norm169 
GTEX-PSDG-1626-SM-48TCQ GTEx-Norm170 
GTEX-Q2AG-0326-SM-48U1O GTEx-Norm171 
GTEX-QDT8-0626-SM-48TYW GTEx-Norm172 
GTEX-QEG5-0726-SM-4R1JQ GTEx-Norm173 
GTEX-QEL4-2126-SM-447AE GTEx-Norm174 
GTEX-QMRM-1626-SM-4R1KV GTEx-Norm175 
GTEX-QVJO-1826-SM-447C9 GTEx-Norm176 
GTEX-R3RS-0626-SM-48FE1 GTEx-Norm177 
GTEX-R53T-1526-SM-48FEK GTEx-Norm178 
GTEX-R55D-0826-SM-48FEA GTEx-Norm179 
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GTEX-REY6-2426-SM-48FF5 GTEx-Norm180 
GTEX-RU1J-0626-SM-4WAWY GTEx-Norm181 
GTEX-RU72-0626-SM-46MUI GTEx-Norm182 
GTEX-RUSQ-2026-SM-4GIAK GTEx-Norm183 
GTEX-RWS6-1926-SM-47JXY GTEx-Norm184 
GTEX-S32W-2026-SM-4AD6E GTEx-Norm185 
GTEX-S33H-0326-SM-4AD6N GTEx-Norm186 
GTEX-S341-1526-SM-4AD6K GTEx-Norm187 
GTEX-S4P3-1326-SM-4AD6V GTEx-Norm188 
GTEX-S4Q7-1126-SM-4AD6R GTEx-Norm189 
GTEX-S4UY-0726-SM-4AD6X GTEx-Norm190 
GTEX-S7SE-0826-SM-4AT4D GTEx-Norm191 
GTEX-SE5C-2126-SM-4BRUJ GTEx-Norm192 
GTEX-T2IS-1526-SM-32QPR GTEx-Norm193 
GTEX-T2YK-2226-SM-32QPT GTEx-Norm194 
GTEX-T5JC-2126-SM-32PMO GTEx-Norm195 
GTEX-T5JW-2026-SM-4DM63 GTEx-Norm196 
GTEX-T6MN-0726-SM-32PML GTEx-Norm197 
GTEX-T6MO-0326-SM-32QOK GTEx-Norm198 
GTEX-TKQ1-0226-SM-33HB5 GTEx-Norm199 
GTEX-TKQ2-1826-SM-33HB2 GTEx-Norm200 
GTEX-TML8-1226-SM-32QON GTEx-Norm201 
GTEX-TMMY-0726-SM-33HBE GTEx-Norm202 
GTEX-U3ZH-1426-SM-4DXSR GTEx-Norm203 
GTEX-U3ZN-1926-SM-4DXSG GTEx-Norm204 
GTEX-U412-1826-SM-4DXTJ GTEx-Norm205 
GTEX-U8XE-0826-SM-4E3J1 GTEx-Norm206 
GTEX-UJHI-1426-SM-3DB9C GTEx-Norm207 
GTEX-UPK5-2326-SM-3P5Z8 GTEx-Norm208 
GTEX-UTHO-1026-SM-3GAF7 GTEx-Norm209 
GTEX-V955-2026-SM-3GAFA GTEx-Norm210 
GTEX-VJWN-0726-SM-3GIJ8 GTEx-Norm211 
GTEX-VUSG-2226-SM-4KKZO GTEx-Norm212 
GTEX-W5X1-2326-SM-3GIL6 GTEx-Norm213 
GTEX-WFON-1826-SM-3GILG GTEx-Norm214 
GTEX-WI4N-1426-SM-3LK7H GTEx-Norm215 
GTEX-WOFL-0826-SM-3MJG1 GTEx-Norm216 
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GTEX-WRHU-0326-SM-3MJFY GTEx-Norm217 
GTEX-WXYG-2226-SM-4E3IM GTEx-Norm218 
GTEX-WY7C-2726-SM-3NB3P GTEx-Norm219 
GTEX-WYBS-0926-SM-3NM94 GTEx-Norm220 
GTEX-WYJK-1326-SM-3NB2T GTEx-Norm221 
GTEX-WYVS-1726-SM-3NMAY GTEx-Norm222 
GTEX-X15G-1626-SM-3NMB3 GTEx-Norm223 
GTEX-X261-0626-SM-3NMD9 GTEx-Norm224 
GTEX-X4EP-2926-SM-3P5YQ GTEx-Norm225 
GTEX-X4XY-0926-SM-4E3JD GTEx-Norm226 
GTEX-XBED-1626-SM-47JYN GTEx-Norm227 
GTEX-XGQ4-0926-SM-4AT4U GTEx-Norm228 
GTEX-XMD1-0826-SM-4AT52 GTEx-Norm229 
GTEX-XMD2-0926-SM-4WWEF GTEx-Norm230 
GTEX-XMK1-1126-SM-4IHJ8 GTEx-Norm231 
GTEX-XOT4-0726-SM-4GIAW GTEx-Norm232 
GTEX-XQ3S-1326-SM-4BOPQ GTEx-Norm233 
GTEX-XQ8I-2426-SM-4WAXY GTEx-Norm234 
GTEX-XUW1-2326-SM-4BOO5 GTEx-Norm235 
GTEX-XUZC-1626-SM-4BRVP GTEx-Norm236 
GTEX-XV7Q-2326-SM-4BRVZ GTEx-Norm237 
GTEX-XYKS-1326-SM-4BRUN GTEx-Norm238 
GTEX-Y111-2026-SM-4SOJA GTEx-Norm239 
GTEX-Y114-2026-SM-4TT7L GTEx-Norm240 
GTEX-Y3I4-1526-SM-4TT7K GTEx-Norm241 
GTEX-Y3IK-2326-SM-4WWDT GTEx-Norm242 
GTEX-Y5LM-1726-SM-4VDSX GTEx-Norm243 
GTEX-Y5V5-2126-SM-4WWFO GTEx-Norm244 
GTEX-Y5V6-2126-SM-4WWFX GTEx-Norm245 
GTEX-Y8E4-1626-SM-5S2MW GTEx-Norm246 
GTEX-Y8LW-1626-SM-5IFHX GTEx-Norm247 
GTEX-Y9LG-1426-SM-5IFJZ GTEx-Norm248 
GTEX-YB5E-1726-SM-5IFJ3 GTEx-Norm249 
GTEX-YB5K-1626-SM-5IFIN GTEx-Norm250 
GTEX-YEC3-1026-SM-5IFI5 GTEx-Norm251 
GTEX-YFC4-1426-SM-5IFJG GTEx-Norm252 
GTEX-YFCO-1826-SM-4W1YH GTEx-Norm253 
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GTEX-YJ8O-2226-SM-5IFHW GTEx-Norm254 
GTEX-ZA64-1526-SM-5CVMD GTEx-Norm255 
GTEX-ZAB4-2526-SM-5HL8M GTEx-Norm256 
GTEX-ZAJG-0626-SM-5HL8X GTEx-Norm257 
GTEX-ZC5H-2626-SM-5J2MG GTEx-Norm258 
GTEX-ZDTT-2126-SM-5S2OJ GTEx-Norm259 
GTEX-ZDXO-0126-SM-5S2ND GTEx-Norm260 
GTEX-ZDYS-1126-SM-5K7UB GTEx-Norm261 
GTEX-ZEX8-2226-SM-57WC6 GTEx-Norm262 
GTEX-ZF29-1926-SM-5S2P1 GTEx-Norm263 
GTEX-ZF2S-2026-SM-5E461 GTEx-Norm264 
GTEX-ZF3C-2326-SM-5S2MZ GTEx-Norm265 
GTEX-ZLFU-2126-SM-4WWEV GTEx-Norm266 
GTEX-ZLV1-1426-SM-4WWES GTEx-Norm267 
GTEX-ZPIC-1126-SM-5BC7F GTEx-Norm268 
GTEX-ZQG8-0726-SM-5P9H9 GTEx-Norm269 
GTEX-ZQUD-1926-SM-51MSA GTEx-Norm270 
GTEX-ZT9W-2026-SM-51MRA GTEx-Norm271 
GTEX-ZTTD-1026-SM-51MRD GTEx-Norm272 
GTEX-ZTX8-1226-SM-4YCE9 GTEx-Norm273 
GTEX-ZU9S-1926-SM-5NQBP GTEx-Norm274 
GTEX-ZUA1-1526-SM-59HLS GTEx-Norm275 
GTEX-ZV6S-1826-SM-5NQ8D GTEx-Norm276 
GTEX-ZV7C-1826-SM-5NQ83 GTEx-Norm277 
GTEX-ZVE2-1226-SM-5NQ8R GTEx-Norm278 
GTEX-ZVT2-1826-SM-5NQ8W GTEx-Norm279 
GTEX-ZVT4-1026-SM-57WC4 GTEx-Norm280 
GTEX-ZVTK-0326-SM-51MRR GTEx-Norm281 
GTEX-ZVZQ-0826-SM-51MRF GTEx-Norm282 
GTEX-ZWKS-2826-SM-5NQ74 GTEx-Norm283 
GTEX-ZXES-0826-SM-5E43C GTEx-Norm284 
GTEX-ZY6K-1626-SM-5GZWV GTEx-Norm285 
GTEX-ZYFC-0826-SM-5E44K GTEx-Norm286 
GTEX-ZYT6-0126-SM-5E45J GTEx-Norm287 
GTEX-ZYW4-0826-SM-5GIDG GTEx-Norm288 
GTEX-ZZ64-1226-SM-5E43R GTEx-Norm289 
GTEX-ZZPU-0626-SM-5E43T GTEx-Norm290 
http://etd.uwc.ac.za/
134 
 
Appendix III 
TCGA Data Curated 
Table 7. 3: Paired TCGA NAT and Primary Tumour Samples 
Complete TCGA 
ID 
Sample Name Sample Name Molecular 
Subtype 
TCGA-BH-A18V Norm1_NAT Tum1_TN Triple Negative 
TCGA-BH-A1EV Norm10_NAT Tum10_ER Estrogen Positive 
TCGA-BH-A18P Norm11_NAT Tum11_ER Estrogen Positive 
TCGA-BH-A1ET Norm12_NAT Tum12_ER Estrogen Positive 
TCGA-BH-A0DP Norm13_NAT Tum13_ER Estrogen Positive 
TCGA-BH-A0E1 Norm14_NAT Tum14_ER Estrogen Positive 
TCGA-BH-A0BJ Norm15_NAT Tum15_ER Estrogen Positive 
TCGA-BH-A0H7 Norm16_NAT Tum16_ER Estrogen Positive 
TCGA-BH-A0BC Norm17_NAT Tum17_ER Estrogen Positive 
TCGA-BH-A0BA Norm18_NAT Tum18_ER Estrogen Positive 
TCGA-BH-A0DH Norm19_NAT Tum19_ER Estrogen Positive 
TCGA-BH-A18Q Norm2_NAT Tum2_TN Triple Negative 
TCGA-BH-A0H9 Norm20_NAT Tum20_ER Estrogen Positive 
TCGA-BH-A0BV Norm21_NAT Tum21_ER Estrogen Positive 
TCGA-BH-A0B8 Norm22_NAT Tum22_ER Estrogen Positive 
TCGA-BH-A0AZ Norm23_NAT Tum23_ER Estrogen Positive 
TCGA-BH-A0BM Norm24_NAT Tum24_ER Estrogen Positive 
TCGA-BH-A0BQ Norm25_NAT Tum25_ER Estrogen Positive 
TCGA-BH-A0BT Norm26_NAT Tum26_ER Estrogen Positive 
TCGA-BH-A0DG Norm27_NAT Tum27_ER Estrogen Positive 
TCGA-BH-A0DO Norm28_NAT Tum28_ER Estrogen Positive 
TCGA-BH-A0DT Norm29_NAT Tum29_ER Estrogen Positive 
TCGA-BH-A0E0 Norm3_NAT Tum3_TN Triple Negative 
TCGA-BH-A0H5 Norm30_NAT Tum30_ER Estrogen Positive 
TCGA-BH-A0HA Norm31_NAT Tum31_ER Estrogen Positive 
TCGA-BH-A18J Norm32_NAT Tum32_ER Estrogen Positive 
TCGA-BH-A18L Norm33_NAT Tum33_ER Estrogen Positive 
TCGA-BH-A1EW Norm34_NAT Tum34_TN Triple Negative 
TCGA-BH-A0AY Norm35_NAT Tum35_ER Estrogen Positive 
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TCGA-BH-A0AU Norm36_NAT Tum36_ER Estrogen Positive 
TCGA-BH-A0B5 Norm37_NAT Tum37_ER Estrogen Positive 
TCGA-BH-A1EN Norm38_NAT Tum38_Her2 Her2-Positive 
TCGA-BH-A1FU Norm39_NAT Tum39_Her2 Her2-Positive 
TCGA-A7-A0CE Norm4_NAT Tum4_TN Triple Negative 
TCGA-BH-A18K Norm40_NAT Tum40_ER Estrogen Positive 
TCGA-A7-A13E Norm5_NAT Tum5_ER Estrogen Positive 
TCGA-BH-A0B3 Norm6_NAT Tum6_TN Triple Negative 
TCGA-BH-A0BW Norm7_NAT Tum7_TN Triple Negative 
TCGA-BH-A0DL Norm8_NAT Tum8_ER Estrogen Positive 
TCGA-E2-A158 Norm9_NAT Tum9_TN Triple Negative 
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Table 7. 4: Unpaired TGCA NAT Samples 
Complete TCGA ID Sample Name Molecular Subtype 
TCGA-E9-A1RH Norm41_NAT Normal - Solid Tissue 
TCGA-BH-A0DQ Norm42_NAT Normal - Solid Tissue 
TCGA-E2-A15M Norm43_NAT Normal - Solid Tissue 
TCGA-E2-A1LS Norm44_NAT Normal - Solid Tissue 
TCGA-BH-A209 Norm45_NAT Normal - Solid Tissue 
TCGA-BH-A0DZ Norm46_NAT Normal - Solid Tissue 
TCGA-AC-A2FM Norm47_NAT Normal - Solid Tissue 
TCGA-BH-A1FR Norm48_NAT Normal - Solid Tissue 
TCGA-E9-A1RC Norm49_NAT Normal - Solid Tissue 
TCGA-A7-A0DB Norm50_NAT Normal - Solid Tissue 
TCGA-BH-A0DK Norm51_NAT Normal - Solid Tissue 
TCGA-GI-A2C8 Norm52_NAT Normal - Solid Tissue 
TCGA-E2-A15K Norm53_NAT Normal - Solid Tissue 
TCGA-E9-A1RD Norm54_NAT Normal - Solid Tissue 
TCGA-BH-A203 Norm55_NAT Normal - Solid Tissue 
TCGA-BH-A0C0 Norm56_NAT Normal - Solid Tissue 
TCGA-BH-A18U Norm57_NAT Normal - Solid Tissue 
TCGA-BH-A1FJ Norm58_NAT Normal - Solid Tissue 
TCGA-E9-A1RF Norm59_NAT Normal - Solid Tissue 
TCGA-BH-A1F2 Norm60_NAT Normal - Solid Tissue 
TCGA-E2-A15I Norm61_NAT Normal - Solid Tissue 
TCGA-BH-A0C3 Norm62_NAT Normal - Solid Tissue 
TCGA-A7-A13G Norm63_NAT Normal - Solid Tissue 
TCGA-E9-A1RI Norm64_NAT Normal - Solid Tissue 
TCGA-E9-A1RB Norm65_NAT Normal - Solid Tissue 
TCGA-A7-A0CH Norm66_NAT Normal - Solid Tissue 
TCGA-BH-A1EO Norm67_NAT Normal - Solid Tissue 
TCGA-E9-A1N5 Norm68_NAT Normal - Solid Tissue 
TCGA-A7-A13F Norm69_NAT Normal - Solid Tissue 
TCGA-E9-A1N9 Norm70_NAT Normal - Solid Tissue 
TCGA-AC-A23H Norm71_NAT Normal - Solid Tissue 
TCGA-E2-A1LB Norm72_NAT Normal - Solid Tissue 
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TCGA-E9-A1N6 Norm73_NAT Normal - Solid Tissue 
TCGA-BH-A1EU Norm74_NAT Normal - Solid Tissue 
TCGA-A7-A0DC Norm75_NAT Normal - Solid Tissue 
TCGA-E2-A153 Norm76_NAT Normal - Solid Tissue 
TCGA-BH-A0BZ Norm77_NAT Normal - Solid Tissue 
TCGA-BH-A1FE Norm78_NAT Normal - Solid Tissue 
TCGA-E9-A1R7 Norm79_NAT Normal - Solid Tissue 
TCGA-BH-A18S Norm80_NAT Normal - Solid Tissue 
TCGA-E9-A1NF Norm81_NAT Normal - Solid Tissue 
TCGA-BH-A208 Norm82_NAT Normal - Solid Tissue 
TCGA-E9-A1N4 Norm83_NAT Normal - Solid Tissue 
TCGA-E2-A1L7 Norm84_NAT Normal - Solid Tissue 
TCGA-BH-A1F8 Norm85_NAT Normal - Solid Tissue 
TCGA-BH-A18R Norm86_NAT Normal - Solid Tissue 
TCGA-AC-A2FB Norm87_NAT Normal - Solid Tissue 
TCGA-BH-A1FC Norm88_NAT Normal - Solid Tissue 
TCGA-BH-A0HK Norm89_NAT Normal - Solid Tissue 
TCGA-AC-A2FF Norm90_NAT Normal - Solid Tissue 
TCGA-E2-A1IG Norm91_NAT Normal - Solid Tissue 
TCGA-E2-A1LH Norm92_NAT Normal - Solid Tissue 
TCGA-GI-A2C9 Norm93_NAT Normal - Solid Tissue 
TCGA-BH-A0DD Norm94_NAT Normal - Solid Tissue 
TCGA-BH-A1FN Norm95_NAT Normal - Solid Tissue 
TCGA-E9-A1NG Norm96_NAT Normal - Solid Tissue 
TCGA-BH-A1FB Norm97_NAT Normal - Solid Tissue 
TCGA-A7-A0D9 Norm98_NAT Normal - Solid Tissue 
TCGA-E2-A1BC Norm99_NAT Normal - Solid Tissue 
TCGA-BH-A1FM Norm100_NAT Normal - Solid Tissue 
TCGA-BH-A1FH Norm101_NAT Normal - Solid Tissue 
TCGA-BH-A1FD Norm102_NAT Normal - Solid Tissue 
TCGA-BH-A0BS Norm103_NAT Normal - Solid Tissue 
TCGA-BH-A18M Norm104_NAT Normal - Solid Tissue 
TCGA-E9-A1ND Norm105_NAT Normal - Solid Tissue 
TCGA-BH-A0B7 Norm106_NAT Normal - Solid Tissue 
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TCGA-BH-A1F0 Norm107_NAT Normal - Solid Tissue 
TCGA-BH-A1FG Norm108_NAT Normal - Solid Tissue 
TCGA-BH-A204 Norm109_NAT Normal - Solid Tissue 
TCGA-BH-A1F6 Norm110_NAT Normal - Solid Tissue 
TCGA-BH-A0DV Norm111_NAT Normal - Solid Tissue 
TCGA-BH-A18N Norm112_NAT Normal - Solid Tissue 
TCGA-E9-A1NA Norm113_NAT Normal - Solid Tissue 
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Table 7. 5: Unpaired TCGA Tumour Samples 
Complete TCGA ID Sample Name Molecular Subtype 
TCGA-BH-A0HL Tum135 Estrogen-Positive 
TCGA-BH-A0RX Tum64 Triple Negative 
TCGA-AO-A0J4 Tum133 Triple Negative 
TCGA-A7-A0DA Tum134 Triple Negative 
TCGA-D8-A142 Tum65 Triple Negative 
TCGA-BH-A0HN Tum41 Estrogen-Positive 
TCGA-A2-A0T0 Tum66 Triple Negative 
TCGA-A2-A0YE Tum67 Triple Negative 
TCGA-A2-A0YJ Tum68 Estrogen-Positive 
TCGA-A2-A0D0 Tum69 Triple Negative 
TCGA-A2-A04U Tum70 Triple Negative 
TCGA-AO-A0J6 Tum71 Triple Negative 
TCGA-A2-A0YM Tum72 Triple Negative 
TCGA-A2-A04Q Tum73 Triple Negative 
TCGA-A2-A0D2 Tum74 Triple Negative 
TCGA-A2-A0SX Tum75 Triple Negative 
TCGA-AO-A0JL Tum76 Triple Negative 
TCGA-AO-A12F Tum77 Triple Negative 
TCGA-BH-A0B9 Tum78 Triple Negative 
TCGA-A2-A04T Tum79 Triple Negative 
TCGA-B6-A0RT Tum80 Triple Negative 
TCGA-AO-A128 Tum81 Triple Negative 
TCGA-AO-A129 Tum82 Triple Negative 
TCGA-AO-A124 Tum83 Triple Negative 
TCGA-B6-A0RU Tum84 Triple Negative 
TCGA-B6-A0IQ Tum85 Triple Negative 
TCGA-B6-A0IJ Tum86 Estrogen Positive 
TCGA-B6-A0X1 Tum87 Triple Negative 
TCGA-B6-A0RE Tum88 Triple Negative 
TCGA-A2-A0ST Tum89 Triple Negative 
TCGA-AR-A0TP Tum42 Estrogen Positive 
TCGA-A1-A0SO Tum90 Triple Negative 
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TCGA-A8-A07C Tum91 Triple Negative 
TCGA-A8-A07O Tum92 Triple Negative 
TCGA-A8-A08H Tum93 Triple Negative 
TCGA-A8-A08R Tum94 Triple Negative 
TCGA-AN-A04D Tum95 Triple Negative 
TCGA-AN-A0AL Tum96 Triple Negative 
TCGA-AN-A0AR Tum97 Triple Negative 
TCGA-AN-A0AT Tum98 Triple Negative 
TCGA-AN-A0FJ Tum99 Estrogen Positive 
TCGA-AN-A0FL Tum100 Triple Negative 
TCGA-AN-A0FX Tum101 Triple Negative 
TCGA-AN-A0G0 Tum102 Triple Negative 
TCGA-AN-A0XU Tum103 Triple Negative 
TCGA-AR-A0TS Tum104 Triple Negative 
TCGA-AR-A0TU Tum105 Triple Negative 
TCGA-AR-A0U0 Tum106 Triple Negative 
TCGA-AR-A0U4 Tum107 Triple Negative 
TCGA-AR-A1AH Tum43 Estrogen Positive 
TCGA-AR-A1AI Tum108 Triple Negative 
TCGA-AR-A1AJ Tum109 Estrogen Positive 
TCGA-AR-A1AQ Tum110 Triple Negative 
TCGA-AR-A1AY Tum111 Triple Negative 
TCGA-BH-A0AV Tum112 Triple Negative 
TCGA-BH-A0BG Tum113 Triple Negative 
TCGA-BH-A0BL Tum114 Triple Negative 
TCGA-BH-A0WA Tum115 Triple Negative 
TCGA-BH-A18G Tum116 Triple Negative 
TCGA-C8-A12K Tum117 Triple Negative 
TCGA-C8-A12V Tum118 Triple Negative 
TCGA-C8-A131 Tum119 Triple Negative 
TCGA-C8-A134 Tum120 Triple Negative 
TCGA-D8-A147 Tum121 Triple Negative 
TCGA-E2-A14N Tum122 Triple Negative 
TCGA-E2-A14R Tum123 Triple Negative 
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TCGA-E2-A14X Tum124 Triple Negative 
TCGA-E2-A150 Tum125 Triple Negative 
TCGA-E2-A159 Tum126 Triple Negative 
TCGA-E2-A1AZ Tum127 Triple Negative 
TCGA-E2-A1B5 Tum128 Estrogen Positive 
TCGA-A8-A08L Tum44 Estrogen Positive 
TCGA-B6-A0IK Tum129 Triple Negative 
TCGA-A8-A08J Tum130 Estrogen Positive 
TCGA-A2-A0T1 Tum137 Her2-Positive 
TCGA-AO-A0J2 Tum131 Triple Negative 
TCGA-BH-A0EE Tum138 Her2-Positive 
TCGA-A2-A0CY Tum45 Estrogen Positive 
TCGA-AO-A12D Tum139 Her2-Positive 
TCGA-AO-A0JE Tum140 Her2-Positive 
TCGA-A2-A0EQ Tum141 Her2-Positive 
TCGA-AO-A03L Tum46 Estrogen Positive 
TCGA-A8-A075 Tum47 Estrogen Positive 
TCGA-A8-A081 Tum48 Estrogen Positive 
TCGA-A8-A08X Tum142 Her2-Positive 
TCGA-A8-A094 Tum49 Estrogen Positive 
TCGA-C8-A12P Tum143 Her2-Positive 
TCGA-C8-A12Z Tum144 Her2-Positive 
TCGA-C8-A137 Tum145 Her2-Positive 
TCGA-E2-A14P Tum146 Her2-Positive 
TCGA-E2-A1B0 Tum147 Her2-Positive 
TCGA-A2-A0CU Tum50 Estrogen Positive 
TCGA-BH-A18T Tum132 Triple Negative 
TCGA-B6-A0X4 Tum51 Estrogen Positive 
TCGA-BH-A0EA Tum52 Estrogen Positive 
TCGA-BH-A18N Tum53 Estrogen Positive 
TCGA-BH-A1EU Tum54 Estrogen Positive 
TCGA-BH-A1EO Tum63 Estrogen Positive 
TCGA-B6-A0WS Tum62 Estrogen Positive 
TCGA-BH-A1ES Tum55 Estrogen Positive 
http://etd.uwc.ac.za/
142 
 
TCGA-B6-A0X0 Tum56 Estrogen Positive 
TCGA-BH-A0DS Tum57 Estrogen Positive 
TCGA-AO-A0JA Tum58 Estrogen Positive 
TCGA-AO-A0JF Tum59 Estrogen Positive 
TCGA-A7-A0CD Tum60 Estrogen Positive 
TCGA-D8-A145 Tum61 Estrogen Positive 
TCGA-AN-A0XW Tum136 Estrogen Positive 
TCGA-B6-A1KF Tum148 Her2-Positive 
TCGA-A2-A1G1 Tum149 Her2-Positive 
TCGA-AR-A24U Tum150 Her2-Positive 
TCGA-C8-A1HK Tum151 Her2-Positive 
TCGA-E2-A1LB Tum152 Her2-Positive 
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